Search Result
Results for "
SAR-COV-2
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
27
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-108044
-
|
Cathepsin
SARS-CoV
|
Metabolic Disease
|
ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with Ki values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC50 value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease .
|
-
-
- HY-108137
-
|
Cathepsin
HSV
SARS-CoV
|
Infection
Inflammation/Immunology
|
Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC50=190 nM) via inhibition of SARS-COV-2 3CL pro protease .
|
-
-
- HY-108137A
-
|
Cathepsin
HSV
SARS-CoV
|
Infection
|
Z-L(D-Val)G-CHN2 is the isoform of Z-LVG-CHN2 (HY-108137). Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC50=190 nM) via inhibition of SARS-COV-2 3CL pro protease .
|
-
-
- HY-149954
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 against SARS-CoV-2 by inhibiting of SKP2 protein and stabilizing BECN1 .
|
-
-
- HY-150783
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-24 (compound 7) is a potent papain-like protease (PL pro) inhibitor. SARS-CoV-2-IN-24 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. SARS-CoV-2-IN-24 can be used for SARS-CoV-2 research .
|
-
-
- HY-155119
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-54 (Compound 2) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-54 has antiviral activity. SARS-CoV-2-IN-54 inhibits SARS-CoV-2 in Vero E6 cells, with an IC50 of 21.4 μM .
|
-
-
- HY-155121
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-56 (Compound 63) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-56 has antiviral activity. SARS-CoV-2-IN-56 inhibits SARS-CoV-2 in Vero E6 cells, with an IC50 of 0.7 μM .
|
-
-
- HY-158687
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-18 (compound 84) is a potent SARS-CoV-2 Mpro inhibitor with the IC50 of 3.23 nM. SARS-CoV-2 Mpro-IN-18 can be used for study of anti-SARS-CoV-2 agent .
|
-
-
- HY-162790
-
|
SARS-CoV
Virus Protease
|
Infection
|
SARS-CoV-2-IN-95 (Compound 10) is an inhibitor for SARS-CoV-2 PLpro with an IC50 of 0.39 μM. SARS-CoV-2-IN-95 exhibits antiviral activity in mouse SARS-CoV-2-infected model .
|
-
-
- HY-156008
-
|
SARS-CoV
Virus Protease
|
Infection
|
SARS-CoV-2-IN-58 (Compound 21H) is an antiviral agent against SARS-CoV-2 (EC50: 18 μM). SARS-CoV-2-IN-58 inhibits SARS-CoV-2 M pro with an IC50 of 0.35 μM .
|
-
-
- HY-163713
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-89 (Compound 2) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-89 enhances IFN-I responses to SARS-CoV-2 infection in A549.hACE2 cells .
|
-
-
- HY-155015
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-45 (Compound 8p) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-45 inhibits SARS-CoV-2 replication in Calu-3 cell with an EC50 of 0.5 μM, and has no evident cytotoxic effect .
|
-
-
- HY-162154
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-75 (compound 13) is a SARS-CoV-2 inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits cellular SARS-CoV-2 replication with an EC68 (half-log reduction in viral titer) of 3 μM .
|
-
-
- HY-163857
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-91 (Compound 194) is an inhibitor for SARS-CoV 2 with an EC50 of 28.92 μM. SARS-CoV-2-IN-91 inhibits the viral -1 programmed ribosome frame shift (-1PRF) element, and thereby inhibits the replication of SARS-CoV 2 .
|
-
-
- HY-168600
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-32 (Compound 1) is a selective inhibitor of SARS-CoV-2 M Pro with an IC50 value of 230 nM. SARS-CoV-2 Mpro-IN-32 can also inhibit the replication of multiple SARS-CoV-2 variants in vitro .
|
-
-
- HY-162604
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-90 (compound 3i) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-90 can be used in coronavirus infection related research .
|
-
-
- HY-155308
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor with an IC50 of 16 µM. SARS-CoV-2-IN-61 has antiviral activities .
|
-
-
- HY-162177
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-78 (compound 3) is an inhibitor for nsp14 of SARS-Cov-2. SARS-CoV-2-IN-78 reveals antiviral activity as N7 methyltrabsferase .
|
-
-
- HY-162777
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-93 (compound 24) is an inhibitor of SARS-CoV-2 and HCoV-OC43. SARS-CoV-2-IN-93 can be used in antiviral research .
|
-
-
- HY-149304
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-40 (Compound 19) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC50s of 100 nM and 160 nM respectively .
|
-
-
- HY-169224
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-100 (Compound 172) is an inhibitor of SARS-CoV-2, demonstrating broad-spectrum antiviral activity against various SARS-CoV-2 variants. SARS-CoV-2-IN-100 exhibits synergistic effects with Nirmatrelvir, which can reduce the risk of antiviral drug resistance .
|
-
-
- HY-146379
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of SARS-CoV-2 with an EC50 of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .
|
-
-
- HY-143417
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-16 (Compound 12) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-16 exhibits potent anti-viral activity with the EC50 of 3.69 μM. SARS-CoV-2-IN-16 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-16 is a potent NPro ligand .
|
-
-
- HY-143418
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-17 (Compound 16) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-17 exhibits potent anti-viral activity with the EC50 of 2.18 μM. SARS-CoV-2-IN-17 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-17 is a potent NPro ligand .
|
-
-
- HY-157022
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-67 (Compound 16), a vitamin K derivatives, has anti-SARS-CoV-2 activity (EC50: 64.8 μM in VeroE6/TMPRSS2 cells). SARS-CoV-2-IN-67 inhibits SARS-CoV-2 RdRp activity .
|
-
-
- HY-157145
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-69 (Compound 7E) is a non-covalent SARS-CoV-2 inhibitor with an EC50 value of 7.4 μM. SARS-CoV-2-IN-69 is a potent inhibitor of SARS-CoV-2 main protease (M pro) and a non-covalent inhibitor of papain (PL pro) .
|
-
-
- HY-163067
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-71 (compound 8h) is a potent inhibitor of SARS-CoV-2. SARS-CoV-2-IN-71 inhibits coronavirus replication at multiple stages. SARS-CoV-2-IN-71 displays anti-coronaviral effect by simultaneously acting on 3CL pro and TMPRSS2 .
|
-
-
- HY-146381
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of SARS-CoV-2 with an EC50 of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases .
|
-
-
- HY-145276
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
|
-
-
- HY-145277
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
|
-
-
- HY-151900
-
|
SARS-CoV
Virus Protease
|
Infection
|
SARS-CoV-2 Mpro-IN-4 is a dual Inhibitor of Main Protease (M Pro) and Cathepsin L (CatL), with IC50s of 900 nM and 60 nM respectively. SARS-CoV-2 Mpro-IN-4 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-4 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 8.2 nM .
|
-
-
- HY-151901
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-5 is a dual Inhibitor of Main Protease (M Pro) and Cathepsin L (CatL), with IC50s of 1800 nM and 145 nM respectively. SARS-CoV-2 Mpro-IN-5 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-5 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 14.7 nM .
|
-
-
- HY-152005
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL pro with an IC50 value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .
|
-
-
- HY-154975
-
|
SARS-CoV
|
Others
|
SARS-CoV-2-IN-49 is an irreversible covalent inhibitor of SARS-CoV-2 main protease .
|
-
-
- HY-162984
-
|
SARS-CoV
|
Cancer
|
SARS-CoV-2-IN-99 (compund 58) is a SARS-CoV-2 main protease inhibitor .
|
-
-
- HY-149315
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-48 (compound 19) is a SARS-CoV-2 inhibitor with an IC50 of 2.7 μM for Omicron BA.1. SARS-CoV-2-IN-48 shows antiviral activities .
|
-
-
- HY-D2342
-
|
Fluorescent Dye
|
Infection
|
SARS-CoV-2 3CLpro probe-1 (Compound probe 3) is a selective and activity-based probe for the SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro probe-1 can detect endogenously expressed 3CLpro in SARS-CoV-2-infected cells .
|
-
-
- HY-168564
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-27 (Compound 9H) is an inhibitor of SARS-CoV-2 3CL pro with an IC50 value of 21 nM. SARS-CoV-2 3CLpro-IN-27 exhibits excellent anti-SARS-CoV-2 replicon activity, demonstrating an EC50 value of 5 nM .
|
-
-
- HY-P3492
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .
|
-
-
- HY-148387
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-35 is a potent and orally active SARS-CoV-2 M pro inhibitor with a Ki value of 12.1 nM. SARS-CoV-2-IN-35 can be used in research of COVID-19 .
|
-
-
- HY-154965
-
SIM0417; SARS-COV-2-IN-41
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-41 (compound 2) is a potent SARS-CoV-2 3CL pro inhibitor with an IC50 value of 0.022 µM. SARS-CoV-2-IN-41 shows antiviral effect .
|
-
-
- HY-149868
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-42 (Compound 8q) is a potent inhibitor of SARS-CoV-2 replication (EC50: 0.4 μM). SARS-CoV-2-IN-42 has no obvious damage to the host cell .
|
-
-
- HY-157144
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-68 (compound 6C) is a covalent SARS-CoV-2 PLpro/Mpro inhibitor with potent antiviral activities. SARS-CoV-2-IN-68 binds to Zn-finger domain of PLpro .
|
-
-
- HY-163628
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-20 (compound MPI100) is a SARS-CoV-2 main protease inhibitor. SARS-CoV-2 Mpro-IN-20 shows antiviral activity with the EC50 of 3.4 μM .
|
-
-
- HY-169200
-
|
SARS-CoV
|
Cancer
|
SARS-CoV-2 Mpro-IN-26 (compund 13) is a covalent inhibitor of SARS-CoV-2 Mpro .
|
-
-
- HY-136298A
-
|
SARS-CoV
|
Infection
|
X77 is a potent non-covalent inhibitor of the main protease of SARS-CoV-2 (SARS-CoV-2 M pro) . X77 binds to SARS-CoV-2 M pro with a Kd value of 0.057 μM [2].
|
-
-
- HY-151267
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC50 of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes .
|
-
-
- HY-154976
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-50 (Compound X77C) is a SARS-CoV-2 main protease (M Pro) inhibitor.. SARS-CoV-2-IN-50 has a high affinity to the catalytic site of M Pro .
|
-
-
- HY-162151
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-74 (compound 30) is a epoxide inhibitor, which inhibits cellular SARS-CoV-2 replication with an EC68 of 5 μM. SARS-CoV-2-IN-74 can be used for the research of coronavirus .
|
-
-
- HY-150681
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp14-IN-2 is a potent SARS-CoV-2 Nsp14 methyltransferase inhibitor with an IC50 value of 0.093 µM. SARS-CoV-2 nsp14-IN-2 shows antiviral activity. SARS-CoV-2 nsp14-IN-2 shows plasma and liver S9 stability. SARS-CoV-2 nsp14-IN-2 has the potential for the research of COVID-19 .
|
-
- HY-150062
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp3-IN-1 (Compound 15c) is a Mac1 (SARS-CoV-2 nsp3 macrodomain) inhibitor with the IC50 value of 6.1 μM. SARS-CoV-2 nsp3-IN-1 can inhibit Mac1 ADP-ribosylhydrolase activity. SARS-CoV-2 nsp3-IN-1 demonstrates notable selectivity for coronavirus macrodomains, especially towards SARS-CoV-2 Mac1 .
|
-
- HY-168557
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-101 (compound 10O) is a potent and orally active SARS-CoV-2 inhibitor with an EC50 value of 0.64 µM for HCoV-229E. SARS-CoV-2-IN-101 shows cyotoxicity. SARS-CoV-2-IN-101 decreases the expression of HCoV-229E N protein and RNA level. SARS-CoV-2-IN-101 shows broad-spectrum anti-coronaviral effect .
|
-
- HY-139732
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-8 is a SARS-CoV-2 main protease inhibitor with an IC50 value of 0.75 μM.
|
-
- HY-169260
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-27 (Compound 4h) is a potent SARS-CoV-2 Mpro inhibitor .
|
-
- HY-146998
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases .
|
-
- HY-163627
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-19 (compound MPI94) is a SARS-CoV-2 MPro inhibitor with the IC50 of 0.096 μM. SARS-CoV-2 Mpro-IN-19 can be used for study of COVID-19 .
|
-
- HY-151988
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-36 is a potent SARS-CoV-2 Mpro (SARS-CoV) inhibitor with an IC50 of 2.37 μM and a Kd of 1.19 μM in enzymatic assays. SARS-CoV-2-IN-36 shows antiviral activity against UC-1074, RG2674, and NVDBB-2220 SARS-CoV-2 variants in Vero cells .
|
-
- HY-151267A
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-25 (Compound CP026) disodium is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC50 of 1.6 μM. SARS-CoV-2-IN-25 disodium inhibits enveloped viruses and liposomes .
|
-
- HY-149264
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-13 is a potent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 21 nM. SARS-CoV-2 3CLpro-IN-13 shows anti-coronavirus activity .
|
-
- HY-139866
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-9 is an inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease.
|
-
- HY-146157
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC50 value of 16.96 µM .
|
-
- HY-155057
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-8 (compound 6b) is an antiviral agent with anti-SARS-CoV-2 properties .
|
-
- HY-149649
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-64 (compound 9), a chenodeoxycholic acid derivative, is a potent inhibitor of spike glycoprotein of SARS-CoV-2 .
|
-
- HY-149799
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-70 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC50 of 3.2 μM .
|
-
- HY-162111
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-73 (compound 4) is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) blocker .
|
-
- HY-163706
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-88 (compound 3a) is a potent SARS-CoV-2 inhibitor with inhibitory value of 96.00% .
|
-
- HY-155983
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp14-IN-4 (Compound 12q) is a selective SARS-CoV-2 nsp14 methyltransferase inhibitor with an IC50 value of 19 ± 2.5 nM. SARS-CoV-2 nsp14-IN-4 (Compound 12q) do not have a zwitterionic character and can penetrate into cells. SARS-CoV-2 nsp14-IN-4 (Compound 12q) can be used for COVID-19 and its causative agent SARS-CoV-2 research .
|
-
- HY-161261
-
|
AAK1
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-81 (compound 12e) is a potent AAK1 inhibitor with an IC50 value of 9.38 nM. SARS-CoV-2-IN-81 shows anti-viral property against SARS-CoV-2. SARS-CoV-2-IN-81 attenuates AAK1-induced phosphorylation of AP2M1 threonine 156 and disrupts the direct interaction between AP2M1 and ACE2, ultimately inhibiting SARS-CoV-2 infection .
|
-
- HY-155540
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally active SARS-CoV-2 3CLpro inhibitor. SARS-CoV-2 3CLpro-IN-14 shows significant anti-SARS-CoV-2 activity (EC50 = 0.18 μM) and low cytotoxicity (CC50 > 50 μM) in Vero E6 cells .
|
-
- HY-149368
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-51 (S-10) is a potent lead compound of Omicron fusion inhibitor. SARS-CoV-2-IN-51 inhibits Omicron and other variants with EC50s of 0.82-5.45 μM. SARS-CoV-2-IN-51 inhibits SARS-CoV-2 virus entry, by the direct interaction with S in the prefusion state .
|
-
- HY-155679
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp14-IN-4 (Compound 12q) is an inhibitor of SARS-CoV-2 nsp14 methyltransferase (IC50=19 nM). SARS-CoV-2 nsp14-IN-4 is non-cytotoxic and cell-permeable. SARS-CoV-2 nsp14-IN-4 is used in COVID-19 research .
|
-
- HY-W760546
-
|
SARS-CoV
Virus Protease
|
Infection
|
SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds .
|
-
- HY-157477
-
|
SARS-CoV
Cathepsin
|
Infection
|
SARS-CoV-2 3CLpro-IN-22 (Compound 17) is a cathepsin L (CTSL ) inhibitor with an IC50 value of 32.5 nM. SARS-CoV-2 3CLpro-IN-22 can be used for the study of SARS-CoV-2 virus .
|
-
- HY-169055
-
|
Virus Protease
|
Infection
Inflammation/Immunology
|
SARS-CoV-2 Mpro-IN-25 (Compound 3a) is a SARS-CoV-2 protease inhibitor with an IC50 value of 0.26 μM. SARS-CoV-2 Mpro-IN-25 exhibits antiviral activity and can be used in pneumonia-related research .
|
-
- HY-157848
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-82 (compound A) is a Programmed-1 ribosomal frameshift (-1 PRF) inhibitor of SARS-CoV-2 .
|
-
- HY-158347
-
-
- HY-163614
-
-
- HY-163186
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-13 (compound 20j) is a covalent SARS-CoV-2 Protease Mpro inhibitor with an IC50 value of 19.0 nM. SARS-CoV-2 Mpro-IN-13 processes antiviral activity with an EC50 value of 138.1 nM .
|
-
- HY-W024485
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-86 (Compound 2734589) is a dual inhibitor of the methyltransferases nsp14 and nsp16 of SARS-CoV-2. SARS-CoV-2-IN-86 exhibits low toxicity with a LD50 of 700 mg/kg according to toxicity analysis predict .
|
-
- HY-144771
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .
|
-
- HY-144772
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .
|
-
- HY-144770
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .
|
-
- HY-155981
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.478 μM). SARS-CoV-2 3CLpro-IN-18 inhibits SARS-CoV-2 in Vero E6 cells (EC50= 2.499 μM) with low cytotoxicity (CC50 > 200 μM) .
|
-
- HY-161238
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-79 (Compound 5) is a SARS-CoV-2 inhibitor, with IC50 and CC50 values of 55 μg/mL and 311.6 μg/mL. SARS-CoV-2-IN-79 has the highest antiviral activity against (hCoV-19/Egypt/NRC-03/2020). SARS-CoV-2-IN-79 can be used for the research of COVID-19 .
|
-
- HY-157805
-
|
PROTACs
SARS-CoV
|
Infection
|
PROTAC SARS-CoV-2 Mpro degrader-2 (Compound 6) is a potent PROTAC degrader of SARS-CoV-2 M pro. PROTAC SARS-CoV-2 Mpro degrader-2 has broad-spectrum antiviral activity against CoVs, including SARS-CoV-2 (EC50 = 10.8 μM), HCoV-OC43 (EC50 = 1.6 μM) and HCoV-229E (EC50 = 6.5 μM). PROTAC SARS-CoV-2 Mpro degrader-2 exhibits potent activity against SARS-CoV-2 in Calu-3 cells, with an EC50 of 0.89 μM .
|
-
- HY-155014
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-44, a inhibitor of SARS-CoV-2, inhibits viral replication, with an EC50 of 0.6μM. SARS-CoV-2-IN-44 has no evident cytotoxic effect in Calu-3 cells and can be used for antiviral research .
|
-
- HY-155654
-
|
SARS-CoV
Virus Protease
|
Infection
|
SARS-CoV-2 Mpro-IN-10 (27h) is a potent M pro inhibitor with IC50 value and EC50 values of 10.9 nM and 43.6 nM, respectively. SARS-CoV-2 Mpro-IN-10 can be used for the research of SARS-CoV-2 virus .
|
-
- HY-163211
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-14 (Compound 19) is an inhibitor of SARS-CoV-2 Mpro with an IC50 of 0.044 μM. SARS-CoV-2 Mpro-IN-14 exhibits water solubility, has no cytotoxicity, and can be used in the study of COVID-19 .
|
-
- HY-132886
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-6 is a SARS-CoV-2 3CLpro inhibitor that shows the most potent enzyme inhibitory IC50 value of 73 nM.
|
-
- HY-149606
-
|
SARS-CoV
|
Infection
|
TKB245 is a highly potent SARS-CoV-2 Mpro inhibitor that effectively blocks SARS-CoV-2 replication in VeroE6 cells .
|
-
- HY-156459
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-12 (compound D026) is a SARS-CoV-2 main protease (Mpro) inhibitor with antiviral activities .
|
-
- HY-162295
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-83 (compound C6E) has excellent activity against SARS CoV-2 spike protein .
|
-
- HY-151269
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-23 is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 induces liposomal membrane disruption with an EC50 value of 4.4 μM .
|
-
- HY-151276
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-29 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 exhibits antiviral activity with IC50s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 induces liposomal membrane disruption with an EC50 value of 3.0 μM .
|
-
- HY-151278
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-30 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 exhibits antiviral activity with IC50s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 induces liposomal membrane disruption with an EC50 value of 6.9 μM .
|
-
- HY-161722
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-21 (compound A8) is a potent SARS-CoV-2 and OVID-19 Main Protease M Pro inhibitor. SARS-CoV-2 Mpro-IN-21 shows excellent antioxidant activity in DPPH assay with an IC50 of 0.36 mg/mL. SARS-CoV-2 Mpro-IN-21 also exhibits better antibacterial potency against Klebsiella with an IC50 of 1.19 mg/mL .
|
-
- HY-147516
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-21 (compound 10), a penicillin sulfone benzyl C6 derivative, is a potent SARS-CoV-2 main protease inhibitor, with an IC50 of 5.3 μM. SARS-CoV-2-IN-21 can be used for COVID-19 research .
|
-
- HY-149314
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-47 (Compound 13) is a SARS-CoV-2 inhibitor (IC50: 0.77 μM against Omicron BA.1, 0.93 μM against Delta strain). SARS-CoV-2-IN-47 can be used for antiviral research .
|
-
- HY-158440
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-17 (compound S5-28) is an orally active and noncovalent SARS-CoV-2 Mpro inhibitor with the EC50 of 1.35 μM. SARS-CoV-2 Mpro-IN-17 can be used for study of COVID-19 .
|
-
- HY-143470
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-18 (Compound 26) is a potent SARS-CoV-2 3C-like protease inhibitor with an IC50 of 45 nM .
|
-
- HY-149955
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-38 (compound 24) is a SARS-CoV-2 inhibitor with good oral bioavailability in mice (F%=39.75%) .
|
-
- HY-162236
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-80 (compound 13) is a potent SARS-CoV-2 3CLpro inhibitor with an IC50 value of 0.964 µM .
|
-
- HY-158422
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-16 (compound 5J) is a SARS-CoV-2 Mpro inhibitor, and inhibits HEK293 cells growth .
|
-
- HY-168568
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-28 (Compound 1K) is an inhibitor of SARS-CoV-2 M pro with an EC50 value of 24 μM .
|
-
- HY-135860
-
|
Virus Protease
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-1 is a potent Mpro inhibitor. SARS-CoV-2-IN-1 inhibits the purified recombinant SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC50s of 0.67, 0.90 and 0.58 μM, respectively .
|
-
- HY-136298
-
|
SARS-CoV
|
Infection
|
(Rac)-X77?is a racemate of X77. X77 is a potent non-covalent inhibitor of the main protease of SARS-CoV-2 (SARS-CoV-2 M pro) . X77 binds to SARS-CoV-2 M pro with a Kd value of 0.057 μM [2].
|
-
- HY-145435
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-12 (Compound 27) is a potent SARS-CoV-2-related 3C-like protease inhibitor (Ki=32.1 pM) for preventing SARS-CoV-2 viral replication and that could be useful in the research of COVID-19 .
|
-
- HY-152108
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-6 is a covalent, irreversible and selective SARS-CoV-2 M pro inhibitor with an IC50 of 0.18 μM. SARS-CoV-2 Mpro-IN-6 does not inhibit human cathepsins B, F, K, and L, and caspase 3 .
|
-
- HY-155016
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-46 is a novel coronavirus (SARS-CoV-2) replication inhibitor with an EC50 of 0.9 μM in Calu-3 cells. SARS-CoV-2-IN-46 has antiviral activity and can be used in novel coronavirus (COVID-19) research .
|
-
- HY-163206
-
|
Cathepsin
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-77 (compound 11e) is a cathepsin L and cathepsin S inhibitor with Ki values of 111 nM and 103 nM, respectively. SARS-CoV-2-IN-77 inhibits SARS-CoV-2 with an EC50 value of 38.4 nM in Calu-3 cells without showing cytotoxicity .
|
-
- HY-159477
-
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
SARS-CoV-2-IN-92 (compound 11) inhibits SARS-CoV-2 variants (EC50 = 0.48 μM), as well as SARS-CoV and MERS-CoV. SARS-CoV-2-IN-92 (compound 11) potently and selectively blocks ERα-Glu II .
|
-
- HY-162956
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-97 (Compound CO-01) is an inhibitor for SARS-CoV-2 Nsp15 endoribonuclease with an IC50 of 53.5 μM. SARS-CoV-2-IN-97 exhibits low cytotoxicity in A549-AT cell with IC50 of 134 μM .
|
-
- HY-139892
-
|
SARS-CoV
|
Infection
|
XR8-69 is a SARS-CoV-2 PLpro inhibitor that shows low micromolar antiviral potency in SARS-CoV-2-infected human cells.
|
-
- HY-141841
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-7 inhibits viral replication with a nanomolar IC50 value (844 nM) in SARS-CoV-2-infected Vero E6 cells.
|
-
- HY-168107
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-98 (compound 38) is a SARS-CoV-2 inhibitor with the Kd
of 0.73 μM and can be used for study of COVID-19 .
|
-
- HY-151271A
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-27 disodium is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 disodium exhibits antiviral activity with IC50s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 disodium induces liposomal membrane disruption with an EC50 value of 6.5 μM .
|
-
- HY-151269A
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-23 disodium is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 disodium exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 disodium induces liposomal membrane disruption with an EC50 value of 4.4 μM .
|
-
- HY-151274
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-28 is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 exhibits antiviral activity with IC50s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 induces liposomal membrane disruption with an EC50 value of 4.4 μM .
|
-
- HY-151271
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-27 is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 exhibits antiviral activity with IC50s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 induces liposomal membrane disruption with an EC50 value of 6.5 μM .
|
-
- HY-151274A
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-28 disodium is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 disodium exhibits antiviral activity with IC50s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 disodium induces liposomal membrane disruption with an EC50 value of 4.4 μM .
|
-
- HY-151276A
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-29 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 disodium exhibits antiviral activity with IC50s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 disodium induces liposomal membrane disruption with an EC50 value of 3.0 μM .
|
-
- HY-151278A
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-30 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 disodium exhibits antiviral activity with IC50s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 disodium induces liposomal membrane disruption with an EC50 value of 6.9 μM .
|
-
- HY-155280
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-60 (compound 5a) is an S-adenosylmethionine (SAM)-competitive and irreversible SARS-CoV-2 nsp16-nsp10 methyltransferase activity inhibitor with an IC50 of 9 μM and a Ki of 26 μM. SARS-CoV-2-IN-60 can specifically occupy a newly identified pocket adjacent to the SAM-binding site on nsp16. SARS-CoV-2-IN-60 has the potential for pan-coronavirus therapeutics .
|
-
- HY-155155
-
|
SARS-CoV
Sigma Receptor
|
Infection
|
SARS-CoV-2-IN-57 (compound (+)-R-26) is a potent inhibitor of SARS-CoV-2 (IC50: 80 nM). SARS-CoV-2-IN-57 has high affinity for Sigma Receptor with Kis of 13.6 nM (S1R) and 14.4 nM (S2R) respectively .
|
-
- HY-168599
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-31 (Compound 18) is an inhibitor of SARS-CoV-2 M Pro with an IC50 value of 11 nM. Additionally, SARS-CoV-2 Mpro-IN-31 effectively inhibits the enzymatic activity of the cysteine proteases cathepsin B and cathepsin L, with IC50 values of 24 nM and 1.8 nM, respectively .
|
-
- HY-147804
-
|
SARS-CoV
Bacterial
Fungal
|
Infection
|
SARS-CoV-2 3CLpro-IN-3 (Compound 3d) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .
|
-
- HY-147805
-
|
SARS-CoV
Bacterial
Fungal
|
Infection
|
SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .
|
-
- HY-155979
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 2.124 μM). SARS-CoV-2 3CLpro-IN-16 binds to the active site and forms a covalent bond with Cys145 of 3CLpro .
|
-
- HY-163742
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-22 (compound 4), a hydrolysable tannin, is a potent SARS-CoV-2 main protease (Mpro) inhibitor with an IC50 value of 1.2 µg/mL. SARS-CoV-2 Mpro-IN-22 does not show any significant cytotoxic activity against A549 and HUVEC cell lines .
|
-
- HY-150789
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-23 (compound GRL-0617) is a SARS-COV-2 papain-like protease (PLpro) inhibitor with an IC50 value of 2.3 μM .
|
-
- HY-152009
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 1.4 µM .
|
-
- HY-153533
-
|
SARS-CoV
|
Infection
|
GRL-1720 is a potent SARS-CoV-2 Mpro inhibitor with an EC50 value of 15 µM. GRL-1720 shows anti-SARS-CoV2 activity .
|
-
- HY-N11896A
-
-
- HY-157439
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-72 (compound 12) is a potent allosteric inhibitor of the SARS-COV-2 papain-like protease domain that can trigger the degradation of NSP3 .
|
-
- HY-157804
-
|
PROTACs
SARS-CoV
|
Infection
|
PROTAC SARS-CoV-2 Mpro degrader-1 (compound 5) is a PROTAC degrader targeting the major SARS-CoV-2 protease with broad-spectrum antiviral activity .
|
-
- HY-150622
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent nsp13 (non-structural protein 13) inhibitor. SARS-CoV-2 nsp13-IN-1 only inhibits nsp13 ssDNA + ATPase, with an IC50 of 6 μM. SARS-CoV-2 nsp13-IN-1 does not inhibit ssDNA - ATPase. SARS-CoV-2 nsp13-IN-1 can be used for COVID-19 research .
|
-
- HY-151477
-
|
SARS-CoV
|
Infection
Cancer
|
SARS-CoV-2-IN-32 (compound 3g) is a COVID-19 inhibitor. SARS-CoV-2-IN-32 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-32 exhibits comparatively high binding affinity (-8.8 Kcal/mole) to COVID-19 main protease (M pro) (PDB ID: 6LU7). SARS-CoV-2-IN-32 can be used in studies of cancer and COVID-19 .
|
-
- HY-151478
-
|
SARS-CoV
|
Infection
Cancer
|
SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor. SARS-CoV-2-IN-33 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-33 exhibits comparatively good binding affinity (-8.0 Kcal/mole) to COVID-19 main protease (M pro) (PDB ID: 6LU7). SARS-CoV-2-IN-33 can be used in studies of cancer and COVID-19 .
|
-
- HY-152589
-
|
SARS-CoV
|
Infection
|
Antiviral agent 25 (compound 6g) is a new non-peptide analog covalent inhibitor of SARS-CoV-2 3CL pro. Antiviral agent 25 has a strong inhibitory effect on SARS-CoV-2 3CL pro and SARS-CoV-2 PL pro with IC50 values of 0.118 µM, 0.448 µM, respectively. Antiviral agent 25 has antiviral effect on SARS-CoV-2 with an EC50 value of 7.249 µM .
|
-
- HY-W728005
-
|
SARS-CoV
|
Infection
|
Covidcil-19 (compound C5) avidly binds to the revised attenuator hairpin structure of the SARS-CoV-2 frameshifting element (FSE) with a Kd of 11 nM. Covidcil-19 stabilizes the hairpin’s folded state and impairs frameshifting in cells. Covidcil-19 reduces frameshifting efficiency of the SARS-CoV-2 FSE and does not affect SARS-CoV-2 FSE RNA levels. Covidcil-19 inhibits a process essential for SARS-CoV-2 viral propagation .
|
-
- HY-157966
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-23 (Compound Cd3) is a compound that can be isolated from Citrus depressa. SARS-CoV-2 3CLpro-IN-23 has good inhibitory activity to the SARS-CoV-2 spike protein, with KD of 0.79 μM. SARS-CoV-2 3CLpro-IN-23 can bind to key amino acid residue, disrupting the formation of the spike protein and h-ACE2 complex .
|
-
- HY-161777
-
|
SARS-CoV
Virus Protease
|
Infection
|
SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2 main protease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC50 of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC50 of 0.02-0.52 μM .
|
-
- HY-150626
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-5 (compound C6) is a potent SARS-CoV-2 nsp13 inhibitor with IC50 values of 50 and 55 μM for ssDNA + ATPase and ssDNA - ATPase. SARS-CoV-2 nsp13-IN-5 can be used for researching anti-COVID-19 .
|
-
- HY-151474
-
|
SARS-CoV
|
Cancer
|
SARS-CoV-2-IN-31 is an effective COVID-19 inhibitor. SARS-CoV-2-IN-31 exhibits excellent to mild activity against various cancer cell lines with IC50 values range from 28.84 to 38.36 μM. SARS-CoV-2-IN-31 can be used for the research of cancer .
|
-
- HY-W348072
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-59 (compound E07), an imidazoline derivative, is a non-peptide small molecule inhibitor of SARS-CoV-2 that targets the main protease (Mpro) of the coronavirus. SARS-CoV-2-IN-59 has a strong interaction with residues on Mpro (Met 165, Gln 166, Met 165, His 41, Gln 189) .
|
-
- HY-156325
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-62 (Compound R3b) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-62 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC50 values of 2.97 μM and 3.82 μM, respectively .
|
-
- HY-156337
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-63 (Compound R3e) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-63 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC50 values of 1.99 μM and 1.92 μM, respectively .
|
-
- HY-144464
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-1 (compound 16b-3) is a potent, selective and irreversible inhibitor of SARS-CoV-2 main protease (Mpro), with an IC50 of 116 nM .
|
-
- HY-155734
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-55(compound 65) is a low cytotoxicity inhibtor of SARS-CoV-2 with an IC50 value of 0.3 μM, by the direct interaction with VSV-S pseudoparticles .
|
-
- HY-149321
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp14-IN-3 (4975) is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 3.5 μM) .
|
-
- HY-155980
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-17 (Compound 3h) is a selective SARS-CoV-2 3CLpro inhibitor (IC50s: 0.322 μM) .
|
-
- HY-157021
-
-
- HY-153533A
-
|
SARS-CoV
|
Infection
|
GRL-1720 TFA is a potent inhibitor of SARS-CoV-2 Mpro with an EC50 value of 15 μM. GRL-1720 TFA shows anti-SARS-CoV2 activity .
|
-
- HY-155527
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent SARS-CoV-2 M pro inhibitor (IC50=0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC50=1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC50>50 μM) .
|
-
- HY-150784
-
|
SARS-CoV
|
Infection
|
XR8-89 is a potent papain-like protease (PL pro) inhibitor with an IC50 value of 0.1 μM. XR8-89 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. XR8-89 can be used for SARS-CoV-2 research .
|
-
- HY-150786
-
|
SARS-CoV
|
Infection
|
PLP_Snyder530 is a potent papain-like protease (PL pro) inhibitor with an IC50 value of 6.4 μM. PLP_Snyder530 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. PLP_Snyder530 can be used for SARS-CoV-2 research .
|
-
- HY-162414
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-84 (compound 20) is aSARS-CoV-2 inhibitor that targets the 3CL protease (3CL Pro) of SARS-CoV-2 (IC50: 369.5 nM ) .
|
-
- HY-144833
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL pro. 3CL pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .
|
-
- HY-150632
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-6 (compound C5) is a potent SARS-CoV-2 non-structural protein 13 (nsp13) inhibitor with IC50 values of 27 and 33 μM for ssDNA + ATPase and ssDNA - ATPase. SARS-CoV-2 nsp13-IN-6 can be used for researching anti-COVID-19 .
|
-
- HY-156007
-
|
SARS-CoV
Virus Protease
|
Infection
|
SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 3CL pro with an IC50 of 0.03 μM. SARS-CoV-2 3CLpro-IN-21 also inhibits SARS-CoV-13CL pro with an IC50 of 0.12μM .
|
-
- HY-156441
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-65 (compound 2f (81)) is a potent,orally active and reversible SARS-CoV-2 entry inhibitor. SARS-CoV-2-IN-65 inhibits the pseudovirus entry in a ACE2-dependent pathway, via mainly inhibiting RBD:ACE2 interaction and TMPRSS2 activity in Calu-3 cells .
|
-
- HY-151608
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-3 is a potent M pro inhibitor with an IC50 value of ﹥5 μM. SARS-CoV-2 Mpro-IN-3 can be used in research of COVID-19 .
|
-
- HY-148705
-
|
SARS-CoV
|
Infection
|
Isomitomycin A is a potential inhibitor against SARS-CoV-2. Isomitomycin A targets to the hACE2 binding site of the modelled surface glycoprotein of SARS-CoV-2. Isomitomycin A can be used in studies of COVID-19 .
|
-
- HY-161919
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-25 (compound 56) inhibits the SARS-CoV-2 3CLpro with the IC50 of 70 nM and displays antiviral activity in cells with the EC50 of 3.1 μM .
|
-
- HY-153719
-
|
SARS-CoV
|
Infection
|
NSC111552 is a potent SARS-CoV-2 NSP14 MTase inhibitor. NSC111552 inhibits the FL-NAH binding to the SARS-CoV-2 NSP14 MTase with an IC50 of 5.1 μM .
|
-
- HY-151535
-
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CL pro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL pro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) .
|
-
- HY-145994
-
ATV006
|
SARS-CoV
|
Infection
|
Obeldesivir (ATV006) is a potent, orally active antiviral agent and ester proagents of GS-441524. Obeldesivir inhibits the replication of SARS-CoV-2 and its variants. Obeldesivir can be used for SARS-CoV-2 research .
|
-
- HY-151990
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2/MERS Mpro-IN-1 (compound 9c) is a potent SARS-CoV-2 and MERS main protease inhibitor with IC50 values of 0.10, 0.06 µM, respectively .
|
-
- HY-151991
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2/MERS Mpro-IN-2 (compound 9d) is a potent SARS-CoV-2 and MERS main protease inhibitor with IC50 values of 0.21, 0.07 µM, respectively .
|
-
- HY-155056
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-7 (compound 6g) is a potent inhibitor of M pro-SARS-CoV-2 (IC50=8.8 μM, CC50=10 μM) .
|
-
- HY-155813
-
|
SARS-CoV
|
Infection
|
MPI60 is a potent SARS-CoV-2 M Pro inhibitor with high antiviral potency, low cellular cytotoxicity, and high in vitro metabolic stability. MPI60 can be used for SARS-CoV-2 research .
|
-
- HY-W423489
-
S-Adenosyl-DL-homocysteine
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-76 (compound 1) is a nsp14-viral cap N7 methyltranferase and PLpro inhibitor of severe acute respiratory syndrome corona virus (SARS-CoV-2) .
|
-
- HY-158405
-
|
SARS-CoV
|
Infection
|
PAV-104 inhibits SARS-CoV-2 replication, with the MOI of 0.01. PAV-104 can interact with SARS-CoV-2 nucleocapsid (N) and interfered with its oligomerization, blocking particle assembly .
|
-
- HY-164868
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-106 (compound 19) is a SARS-CoV-2 papain-like protease inhibitor with the IC50 values of 0.44 μM and 0.18 μM for PLpro enzymatic and viral replication ,respectively .
|
-
- HY-151482
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-2 (compound GC-14) is a selective, low cytotoxic and non-covalent M pro inhibitor (IC50=0.40 μM) with good anti-SARS-CoV-2 activity (EC50=1.1 μM). SARS-CoV-2 Mpro-IN-2 can be used in COVID-19 studies .
|
-
- HY-155187
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-20 (Compound 5g) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.43 μM, Ki: ?0.33?μM) .
|
-
- HY-157305
-
|
SARS-CoV
|
Infection
|
Jun11165 is a SARS-CoV-2 PL pro inhibitor (IC50 ≤ 0.6 μM), which inhibits SARS-CoV-2 with an EC50 value of ≤ 6 μM. Jun11165 can be used in the research of viral infections .
|
-
- HY-168152
-
|
SARS-CoV
Virus Protease
|
Infection
|
SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) is an allosteric inhibitor for SARS-CoV-2 3CLpro with an IC50 of 0.43 μM. SARS-CoV-2 3CLpro-IN-26 exhibits good cell permeability and is able to effectively cross the cell membrane, after co-incubation with Vero-E6 cells .
|
-
- HY-P9807
-
SARS-CR3022; SARS-COV-2 Antibody-CR3022
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein [2].
|
-
- HY-161114
-
|
SARS-CoV
|
Infection
|
MDOLL-0229 (compound 27) is an antiviral agent that targets SARS-CoV-2 Mac1 and repress coronavirus replication. MDOLL-0229 inhibits SARS-CoV-2 Mac1 with an IC50 of 2.1 µM .
|
-
- HY-162914
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-96 (compound 12b) is an inhibitor of HCoV-OC43 (EC50= 97 nM) and SARS-CoV-2 (EC50= 45 nM) and low cytotoxicity (CC50> 10 μM) in Huh7 cells .
|
-
- HY-150680
-
|
SARS-CoV
Histone Methyltransferase
DNA Methyltransferase
|
Infection
|
SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases .
|
-
- HY-152224
-
|
SARS-CoV
|
Infection
|
SPR41 is a potent SARS-CoV-2 main protease inhibitor with Ki values of 0.184, 0.252, 14.4 µM for SARS-CoV-2 M pro, hCatL, hCatB, respectively. SPR41 shows antiviral and cytotoxicity .
|
-
- HY-152220
-
|
SARS-CoV
|
Infection
|
SPR39 is a potent SARS-CoV-2 main protease inhibitor with Ki values of 0.252, 3.38, 7.88 µM for SARS-CoV-2 M pro, hCatL, hCatB, respectively. SPR39 shows antiviral and cytotoxicity .
|
-
- HY-P99710
-
BI 767551; DZIF-10c
|
SARS-CoV
|
Infection
|
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 [2].
|
-
- HY-P5168S
-
|
Isotope-Labeled Compounds
|
Infection
|
GPSVFPLAPSSK- 13C6 is the 13C labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies [2].
|
-
- HY-163785
-
|
SARS-CoV
|
Infection
|
1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructural protein macodomain SARS-CoV-2 NSP3 Mac1 with an IC50 of 30 nM .
|
-
- HY-162924
-
|
SARS-CoV
|
Infection
|
SARS-CoV-IN-6 (Compound 17) is an inhibitor of SARS-CoV-1 and SARS-CoV-2 RdRp, with an IC50 value of 7.8 μM against SARS-CoV-2 RdRp. SARS-CoV-IN-6 reduces cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs), and inhibits SARS-CoV N protein expression, with EC50 values of 0.12 µM for SARS-CoV-1 replicon-based SRIPs and 1.47 µM for SARS-CoV-2 replicon-based SRIPs .
|
-
- HY-151113
-
|
SARS-CoV
|
Infection
|
ZINC000104379474 is a compound that targets SARS-CoV-2 endoribonuclease .
|
-
- HY-145119
-
|
SARS-CoV
|
Infection
|
GS-621763 is an orally available precursor to GS-441524 that exhibits anti-SARS-CoV-2 viral activity in mice. GS-621763 reduces viral load to undetectable levels in ferrets infected with SARS-CoV-2 [2].
|
-
- HY-150623
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-2 (Compound C2) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 42 μM against nsp13 ssDNA + ATPase .
|
-
- HY-150624
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-3 (Compound C3) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 32 μM against nsp13 ssDNA + ATPase .
|
-
- HY-147020
-
NK01-63
|
SARS-CoV
|
Infection
|
Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. The SARS-CoV-2 3CL protease is a critical agent target for small molecule COVID-19, given its likely agentgability and essentiality in the viral maturation and replication cycle .
|
-
- HY-144800
-
|
SARS-CoV
|
Infection
|
FWM-1 is a potent SARS-COV-2 NSP13 helicase enzyme inhibitor with binding free energy equals -328.6 kcal/mol. FWM-1 effectively disrupts the binding of ATP to the SARS-COV2 helicase enzyme .
|
-
- HY-150064
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp3-IN-2 is a macrodomain (Mac1) inhibitor with IC50 value of 180 μM. SARS-CoV-2 nsp3-IN-2 is a small molecule chemical probe and can be used for the research of viral .
|
-
- HY-P99556
-
AZD8895
|
SARS-CoV
|
Infection
|
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
|
-
- HY-133832
-
-
- HY-160943A
-
|
SARS-CoV
|
Infection
|
F594-1001 (compound 6) hydrochloride is a potent and highly selective SARS-CoV-2 Mac1-ADP-ribose inhibitor with IC50s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 hydrochloride directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity .
|
-
- HY-160943
-
|
SARS-CoV
|
Infection
|
F594-1001 (compound 6) is a potent and highly selective SARS-CoV-2 Mac1-ADP-ribose inhibitor with IC50s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity .
|
-
- HY-161837
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-24 (Compound X77) is a inhibitor of SARS-CoV-2 Mpro (IC50=2.8 μM) and also a non-covalent inhibitor of SARS-CoV Mpro (IC50=3.4 μM) .
|
-
- HY-P99103
-
LY-3853113; LY-COV1404
|
SARS-CoV
|
Infection
|
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy [2].
|
-
- HY-N10118
-
|
SARS-CoV
|
Infection
|
NK007 is a novel anti-SARS-CoV-2 agent with an EC50 value of 30 nM.
|
-
- HY-151501
-
-
- HY-P10688
-
-
- HY-162550
-
|
SARS-CoV
|
Infection
|
Jobosic acid, a saturated fatty acid, is a selective SARS-CoV-2 inhibitor. Jobosic acid inhibits Mpro and spike-RBD/ACE-2 interaction with IC50 values of 7.5 μg/mL and 3 μg/mL, respectively. Jobosic acid shows viral entry inhibition for the omicron SARS-CoV-2 variant .
|
-
- HY-155186
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC50s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC50 values between 30-69 nM .
|
-
- HY-146987
-
-
- HY-151497
-
-
- HY-P99604
-
AZD-1061; COV2-2130
|
SARS-CoV
|
Infection
|
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
|
-
- HY-149655
-
|
SARS-CoV
|
Infection
|
D1N8 is a potent SARS-CoV-2 3CL pro inhibitor with an IC50 and CC50 values of 0.44 μM and >20 μM, respectively. D1N8 has the potential for the research of anti-SARS-CoV-2 agents targeting 3CL pro .
|
-
- HY-149767
-
|
SARS-CoV
|
Infection
|
CMX990 is a SARS-CoV-2 3CL protease inhibitor. The EC90s for inhibiting SARS-CoV-2 were 9.6 nM and 101 nM in human bronchial epithelial cells (HBECs) and HeLa-ACE2 cells, respectively. CMX990 has good ADME and pharmacokinetic properties .
|
-
- HY-162464
-
|
PROTACs
SARS-CoV
|
Infection
|
MPD2 is a Cereblon-binding ligand-based PROTAC that degrades MPro, the main protease of SARS-CoV-2. MPD2 effectively reduced MPro protein levels in 293T cells in a time-dependent manner (DC50=296 nM). MPD2 exhibited potent antiviral activity against multiple SARS-CoV-2 strains and had enhanced potency against Nirmatrelvir (HY-138687) resistant strains. MPD2 provides a new direction for antiviral drug development against SARS-CoV-2 and other emerging coronavirus pathogens (Sturcture Note:(Blue: Cereblon ligand (HY-14658), Black: linker (HY-W275882);Red: SARS-CoV-2 MPro Inhibitor MP18 (HY-158763)) .
|
-
- HY-144799
-
-
- HY-151502
-
-
- HY-W753281
-
|
SARS-CoV
|
Infection
|
Dexamethasone metasulfobenzoate sodium is a SARS-CoV-2 exonuclease (ExoN) inhibitor that binds to the catalytic site of ExoN .
|
-
- HY-P99344
-
Anti-Human SARS-COV-2
|
SARS-CoV
|
Infection
|
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
|
-
- HY-162229
-
|
SARS-CoV
|
Infection
|
GRL-190-21 (compound 5e) is an inhibitor for SARS-Cov-2-Mpro with a Ki of 0.04 nM and exhibits antiviral activity in VeroE6 cells with EC50 of 0.26 μM. GRL-190-21 reduces the infectivity, replication, and cytopathic effect of SARS-CoV-2 without significant toxicity .
|
-
- HY-N10604
-
-
- HY-163943
-
|
SARS-CoV
PIKfyve
|
Infection
|
UNI418 is a dual inhibitor of PIKfyve and PIP5K1C with antiviral activity against SARS-CoV-2 (EC50=1.4 μM). UNI418 blocks ACE2-mediated SARS-CoV-2 viral endocytosis by inhibiting PIP5K1C (IC50=60.1 nM; Kd=61 nM). In addition, UNI418 inhibits the proteolytic activation of proteases regulated by PIKfyve (Kd=0.78 nM) to prevent SARS-CoV-2 from entering host cells .
|
-
- HY-162474
-
-
- HY-126085
-
(±)-L-Alliin
|
SARS-CoV
|
Infection
|
(±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of SARS-CoV-2 (Mpro) .
|
-
- HY-P99347
-
-
- HY-156734
-
|
SARS-CoV
Virus Protease
|
Infection
|
D-4-77 is a potent inhibitor of SARS-CoV-2 Mpro with an IC50 value of 0.95 μM. D-4-77 has antiviral active with an EC50 value of 0.49 μM. D-4-77 suppresses SARS-CoV-2 Mpro -induced antagonism of the host NF-κB innate immune response .
|
-
- HY-137984
-
|
SARS-CoV
Apoptosis
|
Cancer
|
Cnicin is an orally bioavailable sesquiterpene lactone. Cnicin has antibacterial and antiproliferative properties and induces apoptosis in primary myeloma cells. Cnicin also exhibits activity against SARS-CoV-2. Cnicin inhibits the viral replication of SARS CoV-2 with an IC50 of 1.18 μg/mL. Cnicin can promote functional nerve regeneration [2] .
|
-
- HY-169092
-
|
SARS-CoV
Virus Protease
|
Infection
|
PF-07957472 (Compound 4) is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor. PF-07957472 shows cytopathic effect in SARS-CoV-2 infected NHBE cells (EC50 = 13.9 nM). PF-07957472 shows antiviral effect in a mouse-adapted model of COVID-19 infection model .
|
-
- HY-N8599
-
|
SARS-CoV
|
Infection
|
Cichoriin is an active compounds against SARS-CoV-2, and may be a potential candidate in researching severe COVID-19 .
|
-
- HY-153121
-
RAY1216
|
SARS-CoV
|
Infection
|
Leritrelvir (RAY1216) is an orally active SARS-CoV-2 main protease slow-tight inhibitor with a Ki of 8.6 nM .
|
-
- HY-157778
-
|
SARS-CoV
|
Infection
|
MK-7845 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 of 8.7 nM .
|
-
- HY-136606
-
|
SARS-CoV
|
Infection
|
SARS-CoV MPro-IN-1 is a SARS-CoV-2 3CLpro covalent inhibitor, with an IC50 of 40 nM. SARS-CoV MPro-IN-1 shows good anti-SARS-CoV-2-infection activity in cell culture with an EC50 of 0.33 μM. SARS-CoV MPro-IN-1 has the potential for COVID-19 research .
|
-
- HY-169171
-
|
Cathepsin
|
Infection
|
Cathepsin L-IN-5 (D6-3) is a potent Cathepsin L (CatL) inhibitor with an IC50 of 0.27 nM. Cathepsin L-IN-5 effectively blocks the CatL function and substantially hinders the entry of the SARS-CoV-2 pseudovirus to cells by inhibiting the cleavage of the spike protein. Cathepsin L-IN-5 can be utilized in SARS-CoV-2 research .
|
-
- HY-168259
-
|
SARS-CoV
|
Infection
|
PLpro-IN-8 (compound 1) is a SARS-CoV papain-like protease (PLpro) inhibitor with IC50 values of 5.9 μM and 0.46 μM for SARS-CoV-2 PLpro and SARS -CoV-1 PLpro, respectively. PLpro-IN-8 inhibits Wuhan strain WK-521 of SARS-CoV-2 with an EC50 of 2.7 μM .
|
-
- HY-149317
-
|
SARS-CoV
|
Infection
|
ZINC475239213 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 20 μM) .
|
-
- HY-149319
-
|
SARS-CoV
|
Infection
|
ZINC61142882 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 6 μM) .
|
-
- HY-N12384
-
|
SARS-CoV
|
Infection
|
Antcin-B is a potent inhibitor of 3CLPro with high affinity. Antcin-B can be used in study SARS-CoV-2 .
|
-
- HY-149656
-
|
SARS-CoV
|
Infection
|
D1N52 is a potent SARS-CoV-2 3CL pro inhibitor with an IC50 of 0.53 μM .
|
-
- HY-14837
-
Enisamium iodide
|
Influenza Virus
SARS-CoV
|
Infection
|
Amizon (Enisamium iodide) is a broad-spectrum antiviral agent for influenza A and B. Amizon is an inhibitor for SARS-CoV-2 RNA polymerase .
|
-
- HY-168584
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-102 (example 58) is a SARS-CoV papain-like protease (PLpro) inhibitor with an IC50 <100 nM .
|
-
- HY-138078
-
PF-07304814
|
SARS-CoV
|
Infection
|
Lufotrelvir (PF-07304814), a phosphate proagent of PF-00835231, acts as a potent 3CLpro protease (Mpro) inhibitor with SARS-CoV-2 antiviral activity. Lufotrelvir binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174nM. Lufotrelvir is promising single antiviral agent and also can be used for the research of combination with other antivirals that target other critical stages of the coronavirus life cycle.
|
-
- HY-104077A
-
GS-5734 maleate
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
Remdesivir maleate, a nucleoside analogue with effective antiviral activity, has EC50s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively. Remdesivir maleate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro [2] .
|
-
- HY-155013
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-43 (Compound 8h) is a potentSARS-CoV-2replication inhibitor with antiviral activity .
|
-
- HY-147845
-
|
SARS-CoV
|
Infection
|
F8-S40 is an inhibitor of SARS-CoV-2 main protease, with an IC50 of 10.88 μM .
|
-
- HY-149322
-
|
SARS-CoV
|
Infection
|
Z795161988 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 2.2 μM) .
|
-
- HY-161365
-
|
SARS-CoV
|
Infection
|
PLpro-IN-2 (Compound 16) is an inhibitor for SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 0.25 μM .
|
-
- HY-133894
-
FB2001
|
SARS-CoV
|
Infection
|
Bofutrelvir (FB2001) is a SARS-CoV-2 main protease M pro inhibitor with an IC50 value of 53 nM and an EC50 value of 0.53 μM. Bofutrelvir exhibits potent antiviral efficacy against several current SARS-CoV-2 variants with EC50 values of 0.26-0.42 μM. Bofutrelvir has an additive antiviral effect when combined with Remdesivir (HY-104077) [2].
|
-
- HY-145644
-
C-135-LS; BMS-986414
|
SARS-CoV
|
Infection
Cancer
|
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
|
-
- HY-158073
-
|
SARS-CoV
|
Infection
|
ML2006a4 is an orally active inhibitor for SARS-CoV-2 main protease (M pro) with IC50 in picomolare value. ML2006a4 is cell permeable and antiviral active, that inhibits replication in SARS-CoV-2 in cells Huh7.5.1-ACE2-TMPRSS2 (Huh7.5.1++) in picomolare level
|
-
- HY-139683
-
|
SARS-CoV
|
Infection
|
Antiviral agent 5 is an intermediate used in antiviral agents targeting 3C and 3CL proteases including SARS-CoV-2 M pro.
|
-
- HY-P99929
-
HFB-30132A
|
SARS-CoV
|
Inflammation/Immunology
|
Enuzovimab (HFB-30132A) is a mAb against SARS-COV-2 Omicron. Enuzovimab binds to spike (S) protein with high affinity .
|
-
- HY-159655
-
-
- HY-169256
-
|
SARS-CoV
|
Infection
|
ZINC4497834 is an inhibitor of SARS-CoV-2 major protease Mpro. ZINC4497834 can be used in anti-COVID19 research .
|
-
- HY-104077
-
GS-5734
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro [2] .
|
-
- HY-150625
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective nsp13 helicase small-molecule inhibitor and inhibit the ssDNA+ ATPase activity of nsp13 with an IC50 value of 57 μM. SARS-CoV-2 nsp13-IN-4 is agentlike molecule with molecular weight of less than 450Da and can provide a broad-spectrum antiviral effect .
|
-
- HY-163029
-
|
Cathepsin
SARS-CoV
|
Infection
|
CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC50s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research .
|
-
- HY-158763
-
TG0205221
|
SARS-CoV
Cathepsin
Virus Protease
|
Infection
|
MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). This dual inhibition enhanced the overall antiviral potency and effect of MPI8. MPI8 can be used in clinical studies of COVID-19 [2].
|
-
- HY-161789
-
|
PROTACs
SARS-CoV
Virus Protease
|
Infection
|
PROTAC SARS-CoV-2 Mpro degrader-3 (Compound P2) exhibits antiviral activity through the degradation of the main protease (Mpro) of human coronaviruses (HCoVs) (DC50=27 μM). PROTAC SARS-CoV-2 Mpro degrader-3 inhibits the viral replication, with EC50 of 4.6 μM, 4.6 μM, and 0.71 μM, for human coronaviruses HCoV-229E, HCoV-OC43 and SARS-CoV-2, respectively. (Pink: ligand for target protein Mpro ligand 2 (HY-161791); Black: linker (HY-161792); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .
|
-
- HY-144747
-
|
SARS-CoV
|
Infection
|
Hydroxyethylamine (Compd VII) is a SARS-CoV-2 3CLpro inhibitor with an IC50 of ~10 μM in the spread assay. Hydroxyethylamine has potent antiviral activities .
|
-
- HY-149320
-
|
SARS-CoV
|
Infection
|
Acryl42-10 is a covalent inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 7 μM) .
|
-
- HY-157539
-
|
SARS-CoV
|
Infection
|
PB49673382 is a SARS-CoV-2 inhibitor. PB49673382 inhibits virus replication and consequent cytopathic effects of the virus with an IC50 of 6.42 μM .
|
-
- HY-163912
-
|
SARS-CoV
|
Infection
|
JZD-07 is a potent SARS-CoV 3CLpro inhibitor. JZD-07 can be used in the study of SARS-CoV-2 infection .
|
-
- HY-163908
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-94 (Compound 6) exhibits antiviral activity against COVID-19 virus by targeting 6VSB protein .
|
-
- HY-169012
-
-
- HY-139311
-
|
SARS-CoV
|
Infection
|
YH-53 is a potent 3CL pro inhibitor with Ki values of 6.3 nM, 34.7 nM for SARS-CoV-1 3CL pro and SARS-CoV-2 3CL pro, respectively. YH-53 strongly blocks the SARS-CoV-2 replication. YH-53 is a peptidomimetic compound with a unique benzothiazolyl ketone. YH-53 has the potential for COVID-19 research [2].
|
-
- HY-N144101
-
|
SARS-CoV
|
Infection
|
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M pro with an IC50 value of 72.07 nM. The main protease (M pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .
|
-
- HY-144647
-
|
SARS-CoV
Virus Protease
|
Infection
|
SP inhibitor 1 (compound 34) is a selective SARS-CoV-2 spike protein (SP) inhibitor with an IC50 of 3.26 μM, >25 μM, >25 μM for SP, M pro and PL pro protein, respectively. SP inhibitor 1 is a vitro SARS-CoV-2 replication inhibitor at non-toxic concentrations (0.3250<5.98 μM). SP inhibitor 1 shows cellular antiviral activity .
|
-
- HY-P99341
-
REGN10933
|
SARS-CoV
|
Infection
|
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms [2].
|
-
- HY-155416
-
|
SARS-CoV
|
Infection
|
M56-S2 iodide is a SARS-CoV-2 M pro inhibitor (IC50=4.0 μM). M56-S2 iodide showed good oral bioavailability and low toxicity in ADMET prediction. M56-S2 iodide has good drug potential and can be used in antiviral (such as SARS-CoV-2) research .
|
-
- HY-161177
-
|
PROTACs
Ras
|
Infection
|
PROTAC KRAS G12D degrades SARS-CoV-2, 3-curd trypsin-like protease (3CLPro). Protac KRAS G12D degrades SARS-CoV-2, 3-curd trypsin-like protease (3CLPRO). The PROTAC molecule is designed by partially coupling a GC-376-based dipeptidyl 3CLPro ligand with pomadomide via a piperazine-piperidine linker .
|
-
- HY-131603
-
3TCTP
|
Reverse Transcriptase
HCV
HBV
SARS-CoV
|
Infection
|
Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the Reverse Transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .
|
-
- HY-125729
-
|
Parasite
SARS-CoV
|
Infection
|
Ivermectin B1b is the minor component of Ivermectin. Ivermectin, a potent anti-parasitic agent, inhibits the replication of SARS-CoV-2 in cell culture [2].
|
-
- HY-100701
-
-
- HY-145592
-
RO7020531; RG7854
|
Toll-like Receptor (TLR)
|
Infection
|
Ruzotolimod is an orally active TLR7 agonist. Ruzotolimod is an immunomodulatory agent that can be used to study HBV, COVID-19, or SARS-CoV-2 infection [2].
|
-
- HY-147844
-
|
SARS-CoV
|
Infection
|
F8-S43-S3 is an inhibitor of SARS-CoV-2 main protease, with an IC50 of 9.69 μM .
|
-
- HY-P99104
-
COVI-AMG; STI-2020
|
SARS-CoV
|
Infection
|
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) [2].
|
-
- HY-162598
-
|
SARS-CoV
|
Infection
|
CET-1 is an antiviral agent that inhibits SARS-CoV-2. CET-1 significantly prevents pseudovirus from entering ACE2 h cells .
|
-
- HY-10241
-
TMC435; TMC435350
|
HCV
HCV Protease
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
|
-
- HY-137048
-
|
SARS-CoV
HIV
HCV
|
Infection
|
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CL pro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CL pro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19. PF-00835231 can inhibit cell infections and also suppress infections in animal models [2] .
|
-
- HY-10241A
-
TMC435 sodium; TMC435350 sodium
|
HCV
HCV Protease
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
|
-
- HY-151265
-
|
SARS-CoV
|
Infection
|
MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077). MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC50s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19 .
|
-
- HY-108986
-
|
Sirtuin
SARS-CoV
|
Cancer
|
JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2 [2].
|
-
- HY-P9802
-
SARS-COV-2 (2019-nCOV) Single-Domain Antibodies; Humanized Single Domain Antibody
|
SARS-CoV
|
Infection
|
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .
|
-
- HY-P990052
-
MAD-0004J08
|
SARS-CoV
|
Infection
|
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .
|
-
- HY-111074
-
MK-0767 analog
|
SARS-CoV
|
Infection
Metabolic Disease
|
DB12055 (MK-0767 analog) is a covalent SARS-CoV-2 3CL protease inhibitor. DB12055 has the potential for the study of dyslipidemia and diabetes mellitus .
|
-
- HY-143216
-
S-217622
|
SARS-CoV
Virus Protease
|
Infection
|
Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) [2].
|
-
- HY-143216A
-
S-217622 fumarate
|
SARS-CoV
Virus Protease
|
Infection
|
Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) [2].
|
-
- HY-124564
-
Marboran
|
SARS-CoV
Orthopoxvirus
|
Infection
|
Methisazone (Marboran) is an antiviral agent that works by inhibiting mRNA and protein synthesis. Methisazone is also a SARS-CoV-2 (COVID-19) inhibitor. Methisazone is mainly used in pox viruses .
|
-
- HY-161070
-
-
- HY-163389
-
|
SARS-CoV
Cathepsin
|
Infection
|
Mpro/Cathepsin L-IN-1 (Compound 4d) is a SARS-CoV-2 M pro/hCatL inhibitor, with Kis of 5.54 μM and 0.701 μM respectively .
|
-
- HY-161791
-
-
- HY-136149A
-
|
SARS-CoV
Virus Protease
|
Infection
|
Mpro inhibitor N3 hemihydrate is a potent inhibitor of SARS-CoV-2 Mpro with an EC50 of 16.77 μM for SARS-CoV-2. Mpro inhibitor N3 hemihydrate specifically inhibits Mpro from multiple coronaviruses, including SARS-CoV and MERS-CoV. Mpro inhibitor N3 hemihydrate displays inhibition against HCoV-229E, FIPV, and MHV-A59 with individual IC50 of 4.0 μM, 8.8 μM, and 2.7 μM, respectively [2].
|
-
- HY-145642
-
ZRC3308-A7
|
SARS-CoV
|
Infection
|
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
- HY-145643
-
ZRC3308-B10
|
SARS-CoV
|
Infection
|
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
- HY-104077R
-
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
Remdesivir (Standard) is the analytical standard of Remdesivir. This product is intended for research and analytical applications. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro [2] .
|
-
- HY-B0462A
-
-
- HY-N2016
-
|
SARS-CoV
Ferroptosis
|
Infection
|
Arteannuin B, No. 2000 can be jointly submitted with the blue material. Arteannuin B had anti-SARS-CoV-2 activity, EC50=10.28 μM [2] .
|
-
- HY-136303
-
|
Drug Metabolite
|
Infection
|
GS-704277 is an alanine metabolite of Remdesivir. Remdesivir, a nucleoside analogue with effective antiviral activity, is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro [2].
|
-
- HY-P99423
-
ADG 20
|
SARS-CoV
|
Infection
|
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
|
-
- HY-P99947
-
XVR011
|
SARS-CoV
|
Infection
|
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .
|
-
- HY-P99889
-
BRII-198
|
SARS-CoV
|
Infection
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2].
|
-
- HY-145641
-
BMS-986413; C-144-LS
|
SARS-CoV
|
Infection
|
Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain .
|
-
- HY-105721
-
|
SARS-CoV
|
Infection
|
Aranotin strongly binds to Nsp15 viral protein. Aranotin can be used as promising SARS-CoV-2 replication strong inhibitor. Aranotin has the potential for COVID-19 research .
|
-
- HY-121068
-
-
- HY-P990705
-
REGN-15160
|
SARS-CoV
|
Inflammation/Immunology
|
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990725
-
|
SARS-CoV
|
Inflammation/Immunology
|
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990768
-
|
SARS-CoV
|
Inflammation/Immunology
|
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-161844
-
|
SARS-CoV
|
Infection
|
Virapinib is a macropinocytosis inhibitor with antiviral activities. Virapinib inhibits macropinocytosis, limiting this entry route for the viruses. Virapinib inhibits infection by SARS-CoV-2, as well as by additional viruses, such as mpox virus and TBEV .
|
-
- HY-158751
-
|
SARS-CoV
|
Infection
|
Jun9-72-2 is a papain (Plpro) inhibitor of SARS-CoV-2 with an IC50 value of 0.67 μM. Jun9-72-2 has antiviral activity .
|
-
- HY-126085R
-
|
SARS-CoV
|
Infection
|
(±)-Alliin (Standard) is the analytical standard of (±)-Alliin. This product is intended for research and analytical applications. (±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of SARS-CoV-2 (Mpro) .
|
-
- HY-160832
-
|
SARS-CoV
|
Infection
|
GC373 is a potent inhibitor of SARS-CoV-2 Mpro that blocks virus replication with an IC50 of 0.4 μM. CG373 can be utilized in anti-COVID-19 research .
|
-
- HY-135114
-
HPCD
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
Hydroxypropyl-beta-cyclodextrin is a SARS-CoV-2 inhibitor. Hydroxypropyl-beta-cyclodextrin has immunomodulatory effects, which can reduce the production of inflammatory cytokines in lung epithelial cells infected by the virus .
|
-
- HY-B0462
-
-
- HY-16762
-
OZ439
|
Parasite
Ferroptosis
SARS-CoV
|
Infection
|
Artefenomel (OZ439) is an orally active, synthetic anti-malarial compound containing an artemisinin pharmacophore with a mechanism of action similar to that of artemisinin. Artefenomel has antiviral activity against SARS-CoV-2 [2].
|
-
- HY-19727A
-
-
- HY-139165
-
|
SARS-CoV
|
Infection
|
AT-9010, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 can inhibit SARS-CoV-2 replication .
|
-
- HY-156655A
-
STI-1558 sodium
|
SARS-CoV
Cathepsin
|
Infection
|
Olgotrelvir sodium is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir sodium can effectively inhibit both SARS-CoV-2 replication and entry into host cells .
|
-
- HY-10241S
-
TMC435-13C,d3; TMC435350-13C,d3
|
Isotope-Labeled Compounds
HCV
HCV Protease
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
Simeprevir- 13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].
|
-
- HY-161356
-
|
SARS-CoV
|
Infection
|
BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC50 for SARS-CoV-2 and HCoV-229E are 0.62 µM and 0.14 µM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir (HY-104077) .
|
-
- HY-139582
-
OC-02
|
nAChR
SARS-CoV
|
Infection
|
Simpinicline (OC-02), a highly selective nicotinic acetylcholine receptor (nAChR) agonist, shows potent antiviral activity against the SARS-CoV-2 variants in cell culture with an IC50 of 0.04 µM .
|
-
- HY-152222
-
|
SARS-CoV
Cathepsin
|
Infection
|
SPR38 is a potent SARS-CoV-2 main protease inhibitor, with a Ki of 0.260 μM. SPR38 also inhibits hCatL and hCatB, with Ki values of 1.92 μM and 11.1 μM, respectively .
|
-
- HY-153228
-
PBI-0451
|
SARS-CoV
|
Infection
|
Pomotrelvir (PBI-0451) is a selective, orally active SARS-CoV-2 3CL protease inhibitor. Pomotrelvir has antiviral activity and can be used in the research of novel coronavirus (COVID-19) .
|
-
- HY-B0462B
-
-
- HY-12648
-
-
- HY-12648A
-
-
- HY-139165B
-
|
SARS-CoV
|
Infection
|
AT-9010 triethylamine, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 triethylamine can inhibit SARS-CoV-2 replication .
|
-
- HY-139165A
-
|
SARS-CoV
|
Infection
|
AT-9010 tetrasodium, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 tetrasodium can inhibit SARS-CoV-2 replication .
|
-
- HY-124439
-
|
Antibiotic
Bacterial
SARS-CoV
|
Infection
Cancer
|
Setomimycin is a potent antibiotic. Setomimycin inhibits the SARS-CoV-2 Mpro enzyme with an IC50 value of 12.02 µM. Setomimycin shows anti-inflammatory and antioxidant properties. Setomimycin shows antiproliferative and antitumor activity [2].
|
-
- HY-149256
-
|
SARS-CoV
|
Infection
|
PLpro/RBD-IN-1 (compound 5) is a dual SARS-CoV-2 PLpro and spike protein RBD inhibitor with IC50s of 7.197 μM and 8.673 μM, respectively .
|
-
- HY-P10344
-
|
Fluorescent Dye
|
Infection
|
MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 is a fluorescent substrate used for fluorescence resonance energy transfer (FRET) protease assays. This substrate is employed to measure the activity of SARS-CoV-2 3CLpro .
|
-
- HY-161792
-
|
PROTAC Linkers
|
Infection
|
N3-C5-O-C-Boc is a linker, which can be utilized for the synthesis of PROTAC SARS-CoV-2 Mpro degrader-3 (HY-161789) .
|
-
- HY-159633
-
|
SARS-CoV
|
Infection
|
PLpro-IN-5 (compound 21) is a PLPro protease inhibitor with an IC50 value of 91.14 nM. PLpro-IN-5 shows broad-spectrum antivirus, especially for SARS-CoV, MERS-CoV, SARS-CoV-2 .
|
-
- HY-105086
-
CP148623
|
SARS-CoV
|
Infection
Metabolic Disease
|
Pamaqueside (CP148623) is a cholesterol absorption inhibitor and a potent binder of the SARS-CoV-2 receptor-binding domain (RBD), which may inhibit viral cellular entry. Pamaqueside can be utilized in metabolic and antiviral research .
|
-
- HY-17542
-
|
SARS-CoV
|
Infection
|
PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with an IC50 of 2.6 µM . PLpro inhibitor inhibits SARS-CoV-2 PLpro with an IC50 of 5.0 µM and an EC50 of 21.0 µM [2].
|
-
- HY-19727
-
-
- HY-136597
-
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
Remdesivir O-desphosphate acetonide impurity is an impurity of Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro [2].
|
-
- HY-N10605
-
|
SARS-CoV
Influenza Virus
|
Infection
|
Maniwamycin E is a maniwamycin derivative isolated from the culture extract of thermotolerant Streptomyces sp. JA74. Maniwamycin E shows antiviral activity against SARS-CoV-2 and influenza (H1N1) virus .
|
-
- HY-B1624
-
Debrisoquine; Isocaramidine; Ro 5-3307/1
|
SARS-CoV
Ser/Thr Protease
|
Infection
Cardiovascular Disease
|
Debrisoquin (Isocaramidine) is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquin can be used for antiviral research .
|
-
- HY-149774
-
|
SARS-CoV
|
Infection
|
GC-78-HCl is an orally and nonpeptidic SARS-CoV-2 M pro inhibitor, with an IC50 of 0.19 μM for enzyme. GC-78-HCl has excellent antiviral activity and favorable pharmacokinetic properties .
|
-
- HY-161790
-
-
- HY-P990711
-
|
SARS-CoV
|
Inflammation/Immunology
|
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P990756
-
|
SARS-CoV
|
Inflammation/Immunology
|
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P990766
-
AZD3152
|
SARS-CoV
|
Inflammation/Immunology
|
Sipavibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P9801
-
SARS-COV-2 (2019-nCOV) Spike RBD Antibody
|
SARS-CoV
|
Infection
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
-
- HY-144798
-
|
SARS-CoV
|
Infection
|
FWM-5 is a potent NSP13 helicase inhibitor. SARS-COV-2 NSP13 helicase enzyme plays crucial role in the virus life cycle. FWM-5 has the potential for the research of infection diseases .
|
-
- HY-150737
-
|
SARS-CoV
|
Infection
|
MI-1851 is a potent furin inhibitor. MI-1851 prevents the proteolytic processing of the S protein of SARS-CoV-2 by endogenous flavoprotease in HEK293 cells. MI-185 has antiviral activity [2].
|
-
- HY-P99435
-
BRII-196
|
SARS-CoV
|
Infection
|
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants [2].
|
-
- HY-P99346
-
CT-P59
|
SARS-CoV
Angiotensin-converting Enzyme (ACE)
|
Infection
|
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
|
-
- HY-P99467
-
BMS 4182137; VIR 7832
|
SARS-CoV
|
Infection
|
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .
|
-
- HY-18234
-
-
- HY-B1624A
-
Debrisoquine hemisulfate; Isocaramidine hemisulfate; Ro 5-3307/1 hemisulfate
|
Endogenous Metabolite
|
Infection
Cardiovascular Disease
|
Debrisoquin (Isocaramidine) hemisulfate is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquin hemisulfate can be used for antiviral research .
|
-
- HY-155136
-
|
SARS-CoV
|
Infection
|
NSC89641 inhibits MERS-CoV M pro, with an IC50 value < 3.5 μM. NSC89641 exhibits the high inhibitory potency against SARS-CoV-2 M pro enzymatic activity, with an IC50 of 3.05 μM .
|
-
- HY-N8306
-
|
Bacterial
PKC
Apoptosis
SARS-CoV
|
Cancer
|
Isojacareubin can be isolated from Hypericum japonicum. Isojacareubin covalently inhibits SARS-CoV-2 3CLpro. Isojacareubin also has anti-helicobacter activity. Isojacareubin inhibits PKC, and suppresses hepatocellular carcinoma metastasis and induces apoptosis [2] .
|
-
- HY-18219
-
-
- HY-13512
-
Camostat mesilate; FOY305; FOY-S980
|
Ser/Thr Protease
SARS-CoV
|
Infection
Inflammation/Immunology
|
Camostat mesylate (Camostat mesilate) is an orally active, synthetic serine protease inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of TMPRSS2, shows antiviral activity against SARS-CoV-2. Camostat mesylate also inhibits the activity of prostasin, trypsin, and matriptase [2] .
|
-
- HY-B1370A
-
(S)-HCQ
|
Parasite
Toll-like Receptor (TLR)
SARS-CoV
Autophagy
|
Infection
|
(S)-Hydroxychloroquine ((S)-HCQ) is the enantiomer of Hydroxychloroquine . Hydroxychloroquine, a synthetic antimalarial agent, inhibits Toll-like receptor 7/9 (TLR7/9) signaling, and shows efficiently inhibits SARS-CoV-2 infection in vitro [2] .
|
-
- HY-139442
-
|
SARS-CoV
|
Infection
|
RdRP-IN-2 is a RNA dependent RNA polymerase (RdRp) inhibitor. RdRP-IN-2 significantly inhibits SARS-CoV-2 RdRp with an IC50 of 41.2 µM.RdRP-IN-2 also inhibits Feline coronavirus (FIPV) replication .
|
-
- HY-144623
-
|
SARS-CoV
|
Infection
|
Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral effects. Antiviral agent 15 inhibits both rabies virus and pseudo-typed SARS-CoV-2 with EC50 values of 1.45 μM and 14.6 μM, respectively .
|
-
- HY-148072
-
|
SARS-CoV
|
Infection
|
MM3122 is a selective type II transmembrane serine protease (TMPRSS2) inhibitor with an IC50 value of 0.34 nM. MM3122 effectively blocks TMPRSS2, thereby inhibiting the entry of SARS-CoV-2 and MERS-CoV into human cells .
|
-
- HY-P5827
-
-
- HY-161619
-
-
- HY-161729
-
|
SARS-CoV
|
Infection
|
PLpro-IN-3 (compound 26R) is a potent Papain-like protease (PLpro) inhibitor with a IC50 of 1.0μM. PLpro-IN-3 exhibits antiviral activity against SARS-CoV-2 with a EC50 of 4.3 μM .
|
-
- HY-162484
-
|
SARS-CoV
Virus Protease
|
Infection
|
GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PL pro), with an IC50 of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC50 range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration Cmax of 549 ng/mL, a half-life T1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse .
|
-
- HY-14434
-
BMS-650032
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-B1370
-
-
- HY-B1370B
-
(R)-HCQ
|
Parasite
Toll-like Receptor (TLR)
SARS-CoV
Autophagy
|
Infection
|
(R)-Hydroxychloroquine is the enantiomer of Hydroxychloroquine . Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro [2] .
|
-
- HY-18234A
-
|
Cathepsin
Ser/Thr Protease
Virus Protease
|
Infection
Inflammation/Immunology
|
Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits M pro (the main protease of SARS-CoV-2) and also has anti-inflammatory activity [2] .
|
-
- HY-100442
-
ABR-215757; ABR 25757
|
SARS-CoV
|
Metabolic Disease
Inflammation/Immunology
|
Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice [2] .
|
-
- HY-131262
-
4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol
|
SARS-CoV
Toll-like Receptor (TLR)
|
Others
|
Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro [2] .
|
-
- HY-131263
-
|
Drug Metabolite
|
Others
|
Hydroxychloroquine Impurity F is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro [2] .
|
-
- HY-D1270
-
|
SARS-CoV
|
Infection
|
Direct Violet 1, an azo dye, is a textile dye. Direct Violet 1 is also the protein-protein interaction (PPI) between the SARS-CoV-2 spike protein and ACE2 inhibitor with IC50s of 1.47-2.63 μM [2].
|
-
- HY-P99376
-
OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)
|
SARS-CoV
|
Infection
|
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
|
-
- HY-N10109A
-
|
SARS-CoV
Parasite
Cathepsin
|
Infection
|
Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC50: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC50: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC50: 50 nM) [2].
|
-
- HY-112894
-
|
JNK
SARS-CoV
|
Inflammation/Immunology
|
ZG-10 (JNK-IN-2) is a JNK inhibitor, with IC50 values of 809 nM, 1140 nM and 709 nM for JNK1, JNK2, and JNK3, respectively. ZG-10 (JNK-IN-2) is a potential anti-SARS-CoV-2 agent [2].
|
-
- HY-B0372A
-
|
SARS-CoV
Autophagy
HIV
|
Metabolic Disease
|
Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions [2] .
|
-
- HY-13433
-
|
Calcium Channel
SARS-CoV
Apoptosis
|
Infection
Cancer
|
Thapsigargin, an endoplasmic reticulum (ER) stress inducer, is an inhibitor of microsomal Ca 2+-ATPase. Thapsigargin efficiently inhibits coronavirus (HCoV-229E, MERS-CoV, SARS-CoV-2) replication in different cell types [2] .
|
-
- HY-138687
-
PF-07321332
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CL PRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research .
|
-
- HY-B0462AS
-
-
- HY-145119S
-
VV116 free base; GS-621763-d1
|
Isotope-Labeled Compounds
|
Others
|
GS-621763-d1 is the deuterium labeled GS-621763 (HY-145119) . GS-621763, an orally bioavailable proagent of GS-441524, shows antiviral activity against SARS-CoV-2 pathogenesis in mice [2].
|
-
- HY-155143
-
|
SARS-CoV
|
Infection
|
CDD-1733 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a Ki of 12 nM. CDD-1733 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants .
|
-
- HY-155142
-
|
SARS-CoV
|
Infection
|
CDD-1819 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a Ki of 5 nM. CDD-1819 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants .
|
-
- HY-155144
-
|
SARS-CoV
|
Infection
|
CDD-1845 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a Ki of 3 nM. CDD-1845 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants .
|
-
- HY-N3445
-
|
SARS-CoV
|
Infection
|
Jaceidin triacetate(compound 54) is a natural compound isolated formmarulabark.Jaceidin triacetatecan inhibitSARS-CoV-2 Mpro, with theIC50of 11.9μM.Jaceidin triacetateinhibits the replication of Sars-Cov-2 Viral in Vero-E6 cells [2].
|
-
- HY-157403
-
|
SARS-CoV
|
Infection
|
Jun12682 is an inhibitor of SARS-CoV-2 papain-like protease. Jun12682 inhibits PL pro with a Ki value of 37.7 nM. Jun12682 has EC50 value of 1.1 μM in the FlipGFP PL pro assay. Jun12682 has orally activity .
|
-
- HY-121068R
-
|
Angiotensin-converting Enzyme (ACE)
SARS-CoV
|
Infection
|
Bisoxatin (Standard) is the analytical standard of Bisoxatin. This product is intended for research and analytical applications. Bisoxatin is a laxative drug used for constipation. Bisoxatin binds substantially at the S-protein-ACE2 interface. Bisoxatin has the potential for inhibiting SARS-CoV-2 entry into the host research .
|
-
- HY-W195509
-
Debrisoquine hydroiodide; Isocaramidine hydroiodide; Ro 5-3307/1 hydroiodide
|
SARS-CoV
Ser/Thr Protease
|
Infection
|
Debrisoquin (hydroiodide) is the hydrochloride form of Debrisoquin (HY-B1624). Debrisoquin is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner. Debrisoquin can be used for antiviral research .
|
-
- HY-17437A
-
-
- HY-161371
-
|
Ser/Thr Protease
|
Cancer
|
VD5123 is a serine protease inhibitor. VD5123 inhibits TMPRS2, HGFA, matriptase, hepsin with IC50s of 15, 3980, 140, 37 nM respectively. VD5123 can be used for antiviral research, such as SARS-CoV-2 and broad panel of coronaviruses and influenza viruses .
|
-
- HY-B0462R
-
|
Histamine Receptor
SARS-CoV
|
Infection
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
Azelastine (hydrochloride) (Standard) is the analytical standard of Azelastine (hydrochloride). This product is intended for research and analytical applications. Azelastine hydrochloridem, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine hydrochloride can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2 [2] .
|
-
- HY-N1996
-
|
COX
Lipoxygenase
SARS-CoV
Influenza Virus
|
Infection
Inflammation/Immunology
|
Chebulagic acid is a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a M2 serine to asparagine 31 mutation (S31N) inhibitor and influenza antiviral. Chebulagic acid also against SARS-CoV-2 viral replication with an EC50 of 9.76 μM.
|
-
- HY-100211
-
TAPI-2
4 Publications Verification
TNF Protease Inhibitor 2
|
MMP
SARS-CoV
|
Cancer
|
TAPI-2 (TNF Protease Inhibitor 2) is a broad-spectrum inhibitor of matrix metalloprotease (MMP), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM), with an IC50 of 20 μM for MMP . TAPI-2 blocks the entry of infectious SARS-CoV .
|
-
- HY-137958A
-
AT-511
|
HCV
SARS-CoV
|
Infection
|
Bemnifosbuvir (AT-511) is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir has pangenotypic antiviral activity [2] .
|
-
- HY-136149
-
|
SARS-CoV
Virus Protease
|
Infection
|
Mpro inhibitor N3 is a potent SARS-CoV-2 MPro inhibitor with an EC50 value of 16.77 µM. Mpro inhibitor N3 shows antiviral activities against HCoV-229E, FIPV, IBV and MHV-A59 [2] .
|
-
- HY-154990
-
|
SARS-CoV
|
Infection
|
RdRP-IN-7 is a RNA-dependent RNA polymerase (RdRp) inhibitor that shows the inhibition of SARS-CoV-2 infection with an IC50 of 8.2 μM, an IC90 of 14.1 μM and an CC90 of 79.1 μM. RdRP-IN-7 can be used for antiviral research .
|
-
- HY-B0190S1
-
|
Ser/Thr Protease
Apoptosis
SARS-CoV
|
Cardiovascular Disease
|
Nafamostat formate salt- 13C6 is the 13C labeled Nafamostat. Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat blocks activation of SARS-CoV-2 [2] .
|
-
- HY-126937
-
|
Parasite
SARS-CoV
|
Infection
|
Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310) . Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 [2].
|
-
- HY-P0012A
-
Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
|
-
- HY-N9351
-
Diphyllin O-glucoside
|
SARS-CoV
|
Infection
Cardiovascular Disease
Metabolic Disease
Cancer
|
Cleistanthin B (Diphyllin O-glucoside) is an orally active arylnaphthalene lignan lactone glycoside. Cleistanthin B exhibits anti-SARS-CoV-2 effects in Vero cells, with EC50 of 6.51 µM. Cleistanthin B also exhibits antitumor, diuretic and antihypertensive effects in vivo [2] .
|
-
- HY-100749
-
|
Flavivirus
Dengue virus
SARS-CoV
|
Infection
|
HeE1-2Tyr, a pyridobenzothiazole compound, is a flavivirus RNA dependent RNA polymerases (RdRp) inhibitor. HeE1-2Tyr significantly inhibits West Nile, Dengue and SARS-CoV-2 RdRps (IC50 of 27.6 µM) activity in vitro [2].
|
-
- HY-P99012
-
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection [2].
|
-
- HY-P4307
-
|
SARS-CoV
|
Infection
|
Antioxidant agent-9 is a peptide with the sequence Asp-Trp. Antioxidant agent-9 shows antioxidant activity. Antioxidant agent-9 also is potential as SARS-CoV-2 antiviral, with an affinity strength equal to Chloroquine (HY-17589A) and Favipiravir (HY-14768) [2].
|
-
- HY-N12697A
-
|
SARS-CoV
Virus Protease
Influenza Virus
Fungal
|
Infection
|
Polycarpine hydrochloride (1a) is a broad-spectrum Mpro inhibitor (IC50 = 30 nM) that can be isolated from the Polycarpa aurata and also serves as an anti-coronaviral agent. Polycarpine hydrochloride possesses antiviral and antifungal activities, with IC50 values of 30.0 nM and 0.12 μM against SARS-CoV-2 Mpro and PEDV Mpro, respectively .
|
-
- HY-10237
-
EBP 520; SCH 503034
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay [2] . Boceprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-17589
-
-
- HY-A0097
-
Antibiotic MDL-507; MDL-507
|
Bacterial
Antibiotic
|
Infection
|
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity [2].
|
-
- HY-W031727S
-
-
- HY-17589A
-
-
- HY-17589B
-
-
- HY-135909
-
TH1217
1 Publications Verification
ZINC1775962367
|
SARS-CoV
|
Infection
Cancer
|
TH1217 (ZINC1775962367) is a potent and selective dCTPase pyrophosphatase 1 (dCTPase) inhibitor, with an IC50 of 47 nM. TH1217 enhances the cytotoxic effect of cytidine analogues in leukemia cells. TH1217 also could modulate SARS-Cov-2 interactors, so it shows activity of against COVID-19 [2].
|
-
- HY-17437
-
-
- HY-P99342
-
REGN10987
|
SARS-CoV
|
Infection
|
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .
|
-
- HY-W031727S1
-
|
Autophagy
SARS-CoV
Toll-like Receptor (TLR)
Parasite
|
Cancer
|
Hydroxychloroquine-d5 is the deuterium labeled Hydroxychloroquine[1]. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].
|
-
- HY-A0097A
-
Antibiotic MDL-507 sodium; MDL-507 sodium
|
Antibiotic
HIV
SARS-CoV
|
Infection
|
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity [2].
|
-
- HY-161068
-
-
- HY-161245
-
|
Virus Protease
Cathepsin
|
Infection
|
FGA146 is a dual, selective inhibitor for M pro and human Cathepsin L, with Kis of 2.19 μM, 0.96 μM and 0.87 μM, for Mal-M pro, pET21-M pro and Cathepsin L, respectively. FGA146 reveals an antiviral activity against SARS-CoV-2 .
|
-
- HY-162504
-
|
SARS-CoV
|
Infection
|
2'-RIBOTAC-U is a ribonuclease (RNase) targeting chimeras (RIBOTACs) and SARS-CoV-2 replication inhibitor. 2'-RIBOTAC-U is composed of a metabolic
handle (Blue), a linker (Black) and a
RNase L recruiter (Pink). RIBOTACs recruits cellular RNases to specific RNA targets, thereby leading to the degradation of these RNAs .
|
-
- HY-162725
-
|
Toll-like Receptor (TLR)
|
Infection
Inflammation/Immunology
|
TLR7 agonist 24 (Compound 21) is an agonist for TLR7 with EC50 of 3.72 μM. TLR7 agonist 24 can be used as a vaccine adjuvant when combined with Aluminum Hydroxide (HY-B1521), that enhances the immune response against SARS-CoV-2 and hepatitis B antigens .
|
-
- HY-14904A
-
|
Influenza Virus
SARS-CoV
|
Infection
|
Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells [2]. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .
|
-
- HY-P0012
-
Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al [2] .
|
-
- HY-135853
-
EIDD-2801; MK-4482
|
SARS-CoV
Influenza Virus
|
Infection
|
Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza [2].
|
-
- HY-N2355
-
|
SARS-CoV
|
Others
|
Solasurine is a steroidal alkaloid that can be isolated from Solanum surrattence. Solasurine can interact with the C3-like protease (SARS-CoV-2 main protease) amino acids Phe8, Pro9, Ile152, Tyr154, Pro293, Phe294, Val297, and Arg298 .
|
-
- HY-16050
-
Aplidine; PM90001
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
Cancer
|
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( KD=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research [2].
|
-
- HY-144260
-
|
SARS-CoV
|
Infection
|
3CPLro-IN-1 (compound A17) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC50 of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .
|
-
- HY-16952
-
(±)-Bepridil; Org 5730
|
Calcium Channel
Sodium Channel
SARS-CoV
|
Infection
Cardiovascular Disease
|
Bepridil ((±)-Bepridil) is a calcium channel blocking agent used as antiarrhythmic agent. Bepridil inhibits both calcium and sodium currents, has research potential in certain ischemia-induced ventricular arrhythmias. Bepridil also has strong inhibition of SARS-CoV-2 from entry and replication inside Vero E6 and A549 cells [2].
|
-
- HY-149267
-
|
STING
SARS-CoV
|
Infection
|
STING agonist-30 is a potent STING agonist. STING agonist-30 exhibits STING-dependent immune activation. STING agonist-30 has extensive inhibitory effects on various viruses, including the herpes simplex virus (HSV), rotavirus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
-
- HY-149940
-
|
SARS-CoV
|
Infection
|
SIMR3030 is a potent SARS-CoV-2 PLpro inhibitor with an IC50 value of 0.0399 µg/mL. SIMR3030 shows antiviral activity. SIMR3030 decreases SARS-CoV spike, ORF1b, IFN-α, IL-6 mRNA expression. SIMR3030 exhibits a satisfactory safety profile in mice .
|
-
- HY-155097
-
|
SARS-CoV
|
Infection
|
ARS-CoV-2-IN-53 (Compd 5d) can inhibit the replication of SARS-CoV-2 with an EC50 value of 14.3 μM. ARS-CoV-2-IN-5 shows significant antiviral activity against human coronavirus 229E (HCoV-229E) .
|
-
- HY-160554
-
|
Liposome
|
Infection
Inflammation/Immunology
|
C12-113 is a lipidoid delivery agent that can be used to transfect siRNA into cells. C12-113 can also be combined with other lipids to form lipid nanoparticles (LNPs) for the delivery of mRNA encoding the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice [2].
|
-
- HY-13512R
-
|
Ser/Thr Protease
SARS-CoV
|
Infection
Inflammation/Immunology
|
Camostat (mesylate) (Standard) is the analytical standard of Camostat (mesylate). This product is intended for research and analytical applications. Camostat mesylate (Camostat mesilate) is an orally active, synthetic serine protease inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of TMPRSS2, shows antiviral activity against SARS-CoV-2. Camostat mesylate also inhibits the activity of prostasin, trypsin, and matriptase [2] .
|
-
- HY-168034
-
|
STING
|
Infection
Inflammation/Immunology
|
diABZI-4 is an oral active STING agonist with broad-spectrum antiviral activity. diABZI-4 induces the production of pro-inflammatory cytokines and lymphocyte activation by activating STING, thereby inhibiting the replication of influenza A virus (IAV), SARS-CoV-2, and human rhinovirus (HRV), with an EC50 range of 11.8-199 nM [2].
|
-
- HY-169220S
-
-
- HY-15148
-
PNU-140690
|
HIV Protease
HIV
SARS-CoV
|
Infection
|
Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM [2]. Tipranavir inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-B0961
-
Mercury dibromofluorescein disodium salt; ZP1
|
Flavivirus
Proteasome
|
Others
|
Merbromin is a mixed inhibitor of the 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2, with an IC50 of 2.7 μM. Merbromin effectively inhibits the replication of the Zika virus (ZIKV) and shows anti-ZIKV activity by inhibiting ZIKVpro. Merbromin can also be used as a topical disinfectant for cuts and scrapes, and it serves as a biological dye [2].
|
-
- HY-B1370S
-
HCQ-d4 (sulfate)
|
Parasite
Toll-like Receptor (TLR)
SARS-CoV
Autophagy
|
Infection
Cancer
|
Hydroxychloroquine-d4 (sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].
|
-
- HY-N7073
-
|
SARS-CoV
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (M pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research [2] .
|
-
- HY-W088075
-
Acriflavinium chloride hydrochloride
|
HIF/HIF Prolyl-Hydroxylase
Bacterial
SARS-CoV
|
Infection
Cancer
|
Acriflavine hydrochloride (Acriflavinium chloride hydrochloride) is a fluorescent acridine dye that can be used to label nucleic acid [2]. Acriflavine hydrochloride is an antiseptic. Acriflavine hydrochloride is a potent HIF-1 inhibitor, with antitumor activity. Acriflavine hydrochloride has antimicrobial and antiviral activities . Acriflavine hydrochloride is a potent papain-like protease (PL pro) inhibitor, which inhibits SARS-CoV-2
|
-
- HY-107577
-
|
HSP
|
Infection
Inflammation/Immunology
Cancer
|
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent Hsp90 inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .
|
-
- HY-144648
-
|
SARS-CoV
|
Infection
|
Mpro/PLpro-IN-1 (Compound 29) is a potent inhibitor of M pro/PL pro. Mpro/PLpro-IN-1 is a dual acting SARS-CoV-2 proteases inhibitor featuring micromolar inhibitory potency versus M pro (IC50 = 1.72 μM) and submicromolar potency versus PL pro (IC50 = 0.67 μM) .
|
-
- HY-144062
-
|
SARS-CoV
|
Infection
|
INSCoV-614(1B) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
|
-
- HY-B0372AS
-
|
Isotope-Labeled Compounds
SARS-CoV
Autophagy
HIV
|
Metabolic Disease
|
Bromhexine-d3 (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions[1][2][3][4].
|
-
- HY-100442S
-
ABR-215757-d5; ABR 25757-d5
|
SARS-CoV
Isotope-Labeled Compounds
|
Metabolic Disease
|
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice [2] .
|
-
- HY-162674
-
|
SARS-CoV
|
Infection
|
MERS-CoV-IN-2 (compound 3c) is a MERS-CoV 3CLpro inhibitor (IC50=17nM). MERS-CoV-IN-2 inhibits the activity of the 3CLpro enzyme by binding to the active site of the enzyme, specifically the S4 subsite, thereby exhibiting antiviral activity against SARS-CoV-2 and MERS-CoV .
|
-
- HY-159890
-
|
SARS-CoV
|
Infection
|
MTI013 is a selective SARS-CoV-2 nsp14 Mtase inhibitor (IC50: 2.98 μM) and an antiviral agent (IC50: 10.33 μM in HCoV-229E-infected Huh7 cells). MTI013 also shows a synergistic antiviral effect with the RdRp inhibitor SHEN26 (HY-155488) .
|
-
- HY-163913
-
|
SARS-CoV
|
Infection
|
SARS-CoV-IN-5 (compound 49) is a highly selective, nonpeptidic and noncovalent 3CL pro inhibitor with IC50s of 38 nM, 21.1 nM and 86 nM for 3CL pro of SARS-CoV-1, SARS-CoV-2, Bat coronavirus WIV1, respectively. SARS-CoV-IN-5 inhibits the replication of the SARS-CoV-2 delta variant with an EC50 of 0.272 μM. SARS-CoV-IN-5 significantly reduces the lung viral copies in a K18-hACE2 transgenic mouse model. SARS-CoV-IN-5 has good target-specific and potential broad-spectrum anticoronavirus activities against SARS-CoV-1, WIV1, MERS, HCoV-OC43, HCoV-229E, and HKU9 .
|
-
- HY-13247
-
ANA598
|
DNA/RNA Synthesis
HCV
SARS-CoV
|
Infection
|
Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition [2].
|
-
- HY-132306
-
CCF981
|
SARS-CoV
Virus Protease
|
Infection
|
CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent SARS-CoV-2 3CL pro (SC2) inhibitor with an IC50 of 68 nM. CCF0058981 inhibits SC1 (SARS-CoV-1 3CL pro) with an IC50 of 19 nM. CCF0058981 has antiviral efficacy and has the potential for COVID-19 research .
|
-
- HY-144263
-
|
SARS-CoV
|
Infection
|
3CPLro-IN-2 (compound C1) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC50 and Ki of 1.55 and 6.09 μM, respectively. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .
|
-
- HY-126419
-
|
SARS-CoV
PKC
|
Infection
|
Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC50 of 1.81 μM and inhibits SARS-CoV-2 viral infection in cells with an EC50 of 71.6 μM. Kobophenol A inhibits the activity of partially purified rat brain protein kinase C (PKC) with an IC50 of 52 µM [2].
|
-
- HY-144061
-
|
SARS-CoV
|
Infection
|
INSCoV-601I(1) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
|
-
- HY-144063
-
|
SARS-CoV
|
Infection
|
INSCoV-600K(1) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
|
-
- HY-14904
-
|
SARS-CoV
Influenza Virus
|
Infection
|
Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells [2]. Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro [2]. Umifenovir shows anti-inflammatory activity .
|
-
- HY-B0693A
-
|
Histamine Receptor
Bacterial
SARS-CoV
|
Infection
|
Ranitidine bismuth citrate is an orally active Histamine H2-receptor antagonist with an IC50 of 3.3 μM. Ranitidine bismuth citrate has high selectivity for SARS-CoV-2-infected cells. Ranitidine bismuth citrate is a commonly used agent anti-Helicobacter pylori infection with an MIC90 value of 16 ng/L [2] .
|
-
- HY-B1370R
-
HCQ sulfate (Standard)
|
Parasite
Toll-like Receptor (TLR)
SARS-CoV
Autophagy
|
Infection
Cancer
|
Hydroxychloroquine (sulfate) (Standard) is the analytical standard of Hydroxychloroquine (sulfate). This product is intended for research and analytical applications. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro [2] .
|
-
- HY-100442S1
-
ABR-215757-d5-1; ABR 25757-d5-1
|
SARS-CoV
Isotope-Labeled Compounds
|
Metabolic Disease
Inflammation/Immunology
|
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice [2] .
|
-
- HY-138687R
-
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
Nirmatrelvir (Standard) is the analytical standard of Nirmatrelvir. This product is intended for research and analytical applications. Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CL PRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research .
|
-
- HY-17437AR
-
|
Parasite
SARS-CoV
Autophagy
Potassium Channel
ROS Kinase
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
Mefloquine (hydrochloride) (Standard) is the analytical standard of Mefloquine (hydrochloride). This product is intended for research and analytical applications. Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine hydrochloride is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine hydrochloride can be used for malaria, systemic lupus erythematosus and cancer research [2] .
|
-
- HY-B0372AR
-
|
SARS-CoV
Autophagy
HIV
|
Metabolic Disease
|
Bromhexine (hydrochloride) (Standard) is the analytical standard of Bromhexine (hydrochloride). This product is intended for research and analytical applications. Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions [2] .
|
-
- HY-B0182
-
-
- HY-101563
-
EPZ015938
|
Histone Methyltransferase
SARS-CoV
MDM-2/p53
CDK
Apoptosis
|
Infection
Cancer
|
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma [2] .
|
-
- HY-10237S
-
EBP 520-d9; SCH 503034-d9
|
Isotope-Labeled Compounds
HCV Protease
HCV
SARS-CoV
|
Infection
|
Boceprevir-d9 is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].
|
-
- HY-108477
-
TMP 1363
|
G-quadruplex
Telomerase
Cholinesterase (ChE)
SARS-CoV
|
Cancer
|
TMPyP4 tosylate (TMP 1363) is a quadruplex-specific ligand. TMPyP4 tosylate inhibits the interaction between G-quadruplexes and IGF-1. TMPyP4 tosylate is a telomerase inhibitor and inhibits cancer cells proliferation. TMPyP4 tosylate is also a stabilizer of nucleic acid secondary structure and an acetylcholinesterase inhibitor. Besides, TMPyP4 tosylate has antiviral activity against SARS-CoV-2 [2] .
|
-
- HY-N0063
-
|
SARS-CoV
HBV
|
Infection
Metabolic Disease
Cancer
|
Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CL pro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19 [2] .
|
-
- HY-W031727
-
|
Parasite
Toll-like Receptor (TLR)
SARS-CoV
Autophagy
|
Infection
Cancer
|
Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling [2] .
|
-
- HY-17589AS
-
-
- HY-137958
-
AT-527
|
HCV
SARS-CoV
|
Infection
|
Bemnifosbuvir hemisulfate (AT-527), a hemisulfate salt of AT-511, a guanosine nucleotide proagent, is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir hemisulfate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir hemisulfate has pangenotypic antiviral activity [2] .
|
-
- HY-17589S1
-
-
- HY-145949
-
|
Drug Metabolite
|
Infection
|
Remdesivir de(ethylbutyl 2-aminopropanoate) is an impurity of Remdesivir. Remdesivir, a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro [2].
|
-
- HY-106560
-
|
COX
SARS-CoV
|
Inflammation/Immunology
|
Proglumetacin is an orally active and potent cyclo-oxygenase inhibitor. Proglumetacin can inhibits SARS-CoV Mpro (main protease of the SARS-CoV-2), with an AC50 of 8.9 μM (activity concentration at half maximal activity). Proglumetacin has anti-inflammatory activity, can be used for inflammation (such as Rheumatoid arthritis, and Allergic air pouch inflammation) research[1][2][3].
|
-
- HY-149050
-
|
Influenza Virus
SARS-CoV
|
Infection
|
Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC90 values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against SARS-CoV-2 infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells .
|
-
- HY-100211A
-
(R)-TNF Protease Inhibitor 2
|
Others
|
Cancer
|
(R)-TAPI-2 is the isomer of TAPI-2 (HY-100211A). TAPI-2 (TNF Protease Inhibitor 2) is a broad-spectrum inhibitor of matrix metalloprotease (MMP), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM), with an IC50 of 20 μM for MMP . TAPI-2 blocks the entry of infectious SARS-CoV .
|
-
- HY-162675
-
|
GSK-3
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
COB-187 is a potent, ATP-competitive and selective inhibitor of GSK-3β. COB-187 inhibits GSK-3 through a reversible and Cysteine (Cys)-199-dependent mechanism. COB-187 inhibits LPS induced cytokine production and SARS-CoV-2 spike protein-induced CXCL10 production .
|
-
- HY-N1996R
-
|
COX
Lipoxygenase
SARS-CoV
Influenza Virus
|
Infection
Inflammation/Immunology
|
Chebulagic acid (Standard) is the analytical standard of Chebulagic acid. This product is intended for research and analytical applications. Chebulagic acid is a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a M2 serine to asparagine 31 mutation (S31N) inhibitor and influenza antiviral. Chebulagic acid also against SARS-CoV-2 viral replication with an EC50 of 9.76 μM.
|
-
- HY-10235
-
VX-950
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide [2] . Telaprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-17589S
-
-
- HY-110066
-
|
Apoptosis
VEGFR
Akt
Angiotensin-converting Enzyme (ACE)
SARS-CoV
FXR
|
Cardiovascular Disease
Cancer
|
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection [2].
|
-
- HY-14904AS
-
|
Isotope-Labeled Compounds
Influenza Virus
SARS-CoV
|
Infection
|
Umifenovir-d6 (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells[1][2]. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity[3].
|
-
- HY-B0462S
-
-
- HY-104077S1
-
GS-5734-d4
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
Remdesivir-d4 is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].
|
-
- HY-124304
-
LOE-908
|
TRP Channel
SARS-CoV
|
Neurological Disease
|
Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity .
|
-
- HY-P3626
-
SPL7013 free base
|
Bacterial
HCV
SARS-CoV
|
Infection
|
Astodrimer (SPL7013 free base) is a large (3-4 nm, ~ 16.5 kDa), negatively charged, highly-branched dendrimer, is a potent virucidal agent. Astodrimer shows antiviral and virucidal activity against a broad spectrum of viruses, including SARS-CoV-2, HIV-1, HSV-1, HSV-2, HPV. Astodrimer also has antibacterial properties [2] .
|
-
- HY-135853S
-
EIDD-2801-d7; MK-4482-d7
|
SARS-CoV
Influenza Virus
|
Inflammation/Immunology
|
Molnupiravir-d7 is the deuterium labeled Molnupiravir. Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].
|
-
- HY-17589R
-
|
Parasite
Autophagy
SARS-CoV
Toll-like Receptor (TLR)
HIV
Antibiotic
|
Infection
Inflammation/Immunology
Cancer
|
Chloroquine (phosphate) (Standard) is the analytical standard of Chloroquine (phosphate). This product is intended for research and analytical applications. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) [2] .
|
-
- HY-155488
-
ATV014
|
SARS-CoV
|
Infection
|
SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC50 for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of
coronavirus disease 2019 (COVID-19) [2].
|
-
- HY-10237R
-
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay [2] . Boceprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-17589AR
-
|
Parasite
Autophagy
SARS-CoV
Toll-like Receptor (TLR)
HIV
Antibiotic
|
Infection
Inflammation/Immunology
Cancer
|
Chloroquine (Standard) is the analytical standard of Chloroquine. This product is intended for research and analytical applications. Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) [2] .
|
-
- HY-159700
-
|
Liposome
|
Infection
|
AA3-DLin is an ionizable cationic lipid with a pKa value of 5.8. AA3-DLin is used to delivery mRNA combined with lipid nanoparticles (LNPs). AA3-DLin LNP COVID-19 vaccines encapsulating SARS CoV-2 spike mRNAs successfully induces strong immunogenicity in a BALB/c mouse model .
|
-
- HY-169222S
-
|
Dihydroorotate Dehydrogenase
ROR
SARS-CoV
|
Infection
|
RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC50 values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively .
|
-
- HY-B0157A
-
HC 20511 fumarate
|
Histamine Receptor
Endogenous Metabolite
SARS-CoV
Influenza Virus
|
Inflammation/Immunology
Endocrinology
Cancer
|
Ketotifen (HC 20-511) fumarate is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen fumarate can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen fumarate also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen fumarate can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention [2] .
|
-
- HY-145119AS
-
VV116; GS-621763-d1 hydrobromide
|
SARS-CoV
RSV
Influenza Virus
|
Infection
|
Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 [2].
|
-
- HY-B0157
-
-
- HY-147336
-
|
Drug Metabolite
|
Infection
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
Desmethylazelastine is a main active metabolite of Azelastine that is oxidatively metabolized by the cytochrome P450 enzyme system with a protein binding rate of 97% and an elimination half-life of 54 hours. Azelastine is an orally active, selective and high-affinity histamine H1-receptor antagonist. Azelastine can be used in studies of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2 [2] .
|
-
- HY-146246
-
4'-FlU; 4'-Fluorouridine
|
RSV
SARS-CoV
HCV
|
Infection
|
EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses [2] .
|
-
- HY-N10661
-
Ipom-F
|
SARS-CoV
|
Infection
Cancer
|
Ipomoeassin F is a potent and selective endoplasmic reticulum (ER) protein-translocation inhibitor by targeting the pore-forming subunit of the Sec61 complex (Sec61α) at the ER membrane. Ipomoeassin F selectively inhibits the ER membrane translocation of SARS-CoV-2 proteins. Ipomoeassin F block the ER translocation of secretory proteins and type I transmembrane proteins (TMPs), but not type III TMPs [2] .
|
-
- HY-P99901
-
VIS649
|
SARS-CoV
|
Inflammation/Immunology
Cancer
|
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) [2] .
|
-
- HY-14904AR
-
|
Influenza Virus
SARS-CoV
|
Infection
|
Umifenovir (hydrochloride) (Standard) is the analytical standard of Umifenovir (hydrochloride). This product is intended for research and analytical applications. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells [2]. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .
|
-
- HY-16050R
-
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
Cancer
|
Plitidepsin (Standard) is the analytical standard of Plitidepsin. This product is intended for research and analytical applications. Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( KD=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research [2].
|
-
- HY-109072
-
|
SARS-CoV
|
Infection
|
Riamilovir is an antiviral drug whose activity is primarily directed against RNA viruses. Riamilovir acts directly on the virus's RNA-dependent RNA polymerase, thereby preventing the virus from replicating. This mechanism allows Riamilovir to effectively reduce the amount of virus, accelerate the relief of symptoms, and help reduce the severity of the disease. Riamilovir can be used in the study of acute respiratory viral infections caused by new variants of SARS-CoV-2 .
|
-
- HY-135853R
-
|
SARS-CoV
Influenza Virus
|
Infection
|
Molnupiravir (Standard) is the analytical standard of Molnupiravir. This product is intended for research and analytical applications. Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza [2].
|
-
- HY-104077S2
-
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
Remdesivir impurity 9-d4 is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].
|
-
- HY-P99340
-
VIR 7831
|
SARS-CoV
|
Infection
Cancer
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease [2].
|
-
- HY-15148S1
-
PNU-140690-d7
|
HIV Protease
HIV
SARS-CoV
Isotope-Labeled Compounds
|
Infection
|
Tipranavir-d7 is deuterated labeled Tipranavir (HY-15148). Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM [2]. Tipranavir inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-15148R
-
|
HIV Protease
HIV
SARS-CoV
|
Infection
|
Tipranavir (Standard) is the analytical standard of Tipranavir. This product is intended for research and analytical applications. Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM [2]. Tipranavir inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-162701
-
|
SARS-CoV
Influenza Virus
RSV
HSV
|
Infection
|
Antiviral agent 58 (Compound J1) is an orally active antiviral agent with broad-spectrum antiviral activity against enveloped viruses, including influenza A virus (IAV), respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human coronavirus OC43 (HCoV-OC43), herpes simplex virus type 1 (HSV-1), and HSV-2 .
|
-
- HY-118326
-
|
Others
|
Cancer
|
MRT 68601 is a potent TBK1 inhibitor with the activity of inhibiting autophagosome formation in lung cancer cells. MRT 68601 may have potential effects against targets associated with host-dependent factors identified in SARS-CoV-2 infection. The drug targets involved in MRT 68601 are related to existing FDA-approved drugs and compounds in clinical trials, which can provide support for the development of broad-spectrum antiviral therapies .
|
-
- HY-15298
-
MK-5172
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively [2]. Grazoprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-15298A
-
MK-5172 potassium salt
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively [2]. Grazoprevir potassium salt inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-15298C
-
MK-5172 sodium salt
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively [2]. Grazoprevir sodium salt inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-18649
-
BCX4430 hydrochloride; Immucillin-A hydrochloride
|
DNA/RNA Synthesis
SARS-CoV
Filovirus
|
Infection
|
Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir hydrochloride is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir hydrochloride inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM [2] .
|
-
- HY-18649A
-
BCX4430; Immucillin-A
|
DNA/RNA Synthesis
SARS-CoV
Filovirus
|
Infection
|
Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM [2] .
|
-
- HY-12473
-
|
PI3K
SARS-CoV
|
Cancer
|
Vps34-IN-2 is a novel, potent and selective inhibitor of Vps34 with IC50s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively . Vps34-IN-2 shows antiviral activity against SARS-CoV-2 (IC50 of 3.1 μM), HCoV-229E (IC50 of 0.7 μM) and HCoV-OC43 [2].
|
-
- HY-15298B
-
MK-5172 hydrate
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively [2]. Grazoprevir hydrate inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-10235S
-
VX-950-d4
|
Isotope-Labeled Compounds
HCV Protease
HCV
SARS-CoV
|
Infection
|
Telaprevir-d4 is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].
|
-
- HY-144120
-
|
SARS-CoV
|
Infection
|
αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist . RBD: receptor-binding domain
|
-
- HY-W028142
-
|
5-HT Receptor
SARS-CoV
|
Neurological Disease
|
Quipazine is a 5-HT agonist with a Ki value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine shows antiviral activity against SARS-CoV-2 with an EC50 of 31.64 μM. Quipazine behaves as a 5-HT3R agonist in peripheral models. Quipazine can be used for neurological disease research [2] .
|
-
- HY-108447
-
|
Ser/Thr Protease
SARS-CoV
PAI-1
|
Infection
Cancer
|
BC-11 hydrobromide is a selective TMPRSS2 inhibitor (TMPRSS2 is a key host cellular factor for viral entry and SARS-CoV-2 pathogenesis), and a selective urokinase (uPA) inhibitor (IC50=8.2 μM). BC-11 hydrobromide is cytotoxic to triple-negative MDA-MB231 breast cancer cells. BC-11 hydrobromide is used in research on viral infections and cancer [2] .
|
-
- HY-14904R
-
|
SARS-CoV
Influenza Virus
|
Infection
|
Umifenovir (Standard) is the analytical standard of Umifenovir. This product is intended for research and analytical applications. Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells [2]. Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro [2]. Umifenovir shows anti-inflammatory activity .
|
-
- HY-B0182R
-
|
Nucleoside Antimetabolite/Analog
SARS-CoV
Virus Protease
FAAH
Ceramidase
Glutathione Peroxidase
|
Infection
Inflammation/Immunology
Cancer
|
Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) [2] .
|
-
- HY-161793
-
|
E3 Ligase Ligand-Linker Conjugates
|
Infection
|
(S,R,S)-AHPC-NHCO-C-O-C5-N3 is a conjugate of ligand for E3 ligase (HY-125845) and linker (HY-161792). (S,R,S)-AHPC-NHCO-C-O-C5-N3 can be utilized for synthesis of PROTAC SARS-CoV-2 Mpro degrader-3 (HY-161789) .
|
-
- HY-N0063R
-
|
SARS-CoV
HBV
|
Infection
Metabolic Disease
Cancer
|
Punicalagin (Standard) is the analytical standard of Punicalagin. This product is intended for research and analytical applications. Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CLpro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19 [2] .
|
-
- HY-A0081
-
|
Dopamine Receptor
SARS-CoV
Sodium Channel
|
Neurological Disease
Cancer
|
Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 [2] .
|
-
- HY-112163
-
eFT226
|
Eukaryotic Initiation Factor (eIF)
SARS-CoV
Apoptosis
|
Infection
Cancer
|
Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex . Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC90=37 nM) [2]. Zotatifin induces cell apoptosis .
|
-
- HY-119980
-
|
Sodium Channel
Dopamine Receptor
SARS-CoV
|
Infection
Neurological Disease
Cancer
|
Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 [2] .
|
-
- HY-101046
-
Quipazine dimaleate
|
5-HT Receptor
SARS-CoV
|
Neurological Disease
|
Quipazine dimaleate is a 5-HT agonist with a Ki value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine dimaleate shows antiviral activity against SARS-CoV-2 with an EC50 of 31.64 μM. Quipazine dimaleate behaves as a 5-HT3R antagonist in peripheral models. Quipazine dimaleate can be used for neurological disease research [2] .
|
-
- HY-152955
-
|
STING
|
Infection
Inflammation/Immunology
|
STING agonist-22 (CF501) is a potent non-nucleotide STING agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research .
|
-
- HY-156654
-
PF-07817883
|
SARS-CoV
Virus Protease
|
Infection
|
Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 main protease (M pro and 3CL pro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19 [2] .
|
-
- HY-100546
-
|
Histone Demethylase
|
Infection
Metabolic Disease
Cancer
|
GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis [2] .
|
-
- HY-157154
-
|
SARS-CoV
|
Infection
|
MAT-POS-e194df51-1 is an orally active, non-covalent and non-peptide SARS-CoV-2 main protease (M pro) inhibitor with an IC50 value of 37nM. MAT-POS-e194df51-1 is cytotoxic with EC50 values of 64 nM and 126 nM in A549-ACE2-TMPRSS2 cells and HeLa -ACE2 cells, respectively .
|
-
- HY-119980B
-
|
Dopamine Receptor
Sodium Channel
SARS-CoV
|
Neurological Disease
Cancer
|
Fluphenazine hydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine hydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine hydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine hydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine hydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 [2] .
|
-
- HY-B0157AR
-
|
Histamine Receptor
Endogenous Metabolite
SARS-CoV
Influenza Virus
|
Inflammation/Immunology
Endocrinology
Cancer
|
Ketotifen (fumarate) (Standard) is the analytical standard of Ketotifen (fumarate). This product is intended for research and analytical applications. Ketotifen (HC 20-511) fumarate is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen fumarate can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen fumarate also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen fumarate can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention [2] .
|
-
- HY-162719
-
|
SARS-CoV
|
Infection
|
RH12 is a dual inhibitor for SARS-CoV-2 related RNA-dependent RNA polymerase (RdRp, IC50 is 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC50 is 4.2 nM). RH12 exhibits antiviral efficacy. RH12 inhibits viral replication and absorption, and exhibits a 90.5% virucidal effects on Vero-E6 cells. RH12 inhibits cell viability of Calu-3 with an IC50 of 17.5 nM .
|
-
- HY-110066R
-
|
Apoptosis
VEGFR
Akt
Angiotensin-converting Enzyme (ACE)
SARS-CoV
FXR
|
Cancer
|
(Z)-Guggulsterone (Standard) is the analytical standard of (Z)-Guggulsterone. This product is intended for research and analytical applications. (Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection [2].
|
-
- HY-B1400
-
Iodoquinol; 5,7-Diiodo-8-hydroxyquinoline; 5,7-Diiodo-8-quinolinol
|
Parasite
SARS-CoV
|
Infection
Inflammation/Immunology
|
Diiodohydroxyquinoline (Iodoquinol, 5,7-Diiodo-8-hydroxyquinoline, 5,7-Diiodo-8-quinolinol) has an orally active and satisfactory antiparasitic properties. Diiodohydroxyquinoline exhibits mutagenic potential in mice and potent anti-SARS-CoV-2 activity with an EC50 value of 1.38 μM in VeroE6 cells. Diiodohydroxyquinoline's antimutagen is ascorbic acid. Diiodohydroxyquinoline is promising for research in inflammationin, testinal amebiasis, amebic liver abscess and chronic nonspecific diarrheas [2] .
|
-
- HY-117626
-
|
AAK1
Cyclin G-associated Kinase (GAK)
SARS-CoV
|
Infection
Neurological Disease
Inflammation/Immunology
|
LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a modest inhibitor of GAK (IC50=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research .
|
-
- HY-152101
-
|
SARS-CoV
|
Infection
|
LY1 is a potent, selective and covalent inhibitor against both SARS-CoV-2 PL pro and M pro with Kd values of 1.5 μM and 2.3 μM for M pro C145A protein and PL pro C111A protein, respectively. LY1 potent against the viral proteases, with IC50s of 0.12 μM and 0.99 μM against M pro and PL pro. LY1 shows high selectivity over other kinases, human proteases and metalloenzyme .
|
-
- HY-N12110
-
|
Toll-like Receptor (TLR)
SARS-CoV
|
Infection
|
SMU-CX1 is a specific TLR3 inhibitor (IC50: 0.11 μM) with IC50 ranging from 0.14-0.33 μM against multiple influenza A virus subtypes. SMU-CX1 inhibits the viral PB2 and NP proteins with an IC50 of 0.43 μM for SARS-CoV-2 activity. SMU-CX1 also inhibits inflammatory factors in host cells, including IFN-β, IP-10, and CCL-5 .
|
-
- HY-19627
-
S-297995
|
Opioid Receptor
|
Neurological Disease
Metabolic Disease
|
Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors [2]. Naldemedine can be used in opioid-induced constipation (OIC) research [2]. Naldemedine is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
|
-
- HY-19627A
-
S-297995 tosylate
|
Opioid Receptor
|
Neurological Disease
Metabolic Disease
|
Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors [2]. Naldemedine can be used in opioid-induced constipation (OIC) research [2]. Naldemedine tosylate is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
|
-
- HY-119980A
-
|
Dopamine Receptor
Sodium Channel
SARS-CoV
|
Infection
Neurological Disease
Cancer
|
Fluphenazine dimaleate is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dimaleate blocks neuronal voltage-gated sodium channels. Fluphenazine dimaleate acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dimaleate can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dimaleate can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 [2] .
|
-
- HY-119980S
-
|
Isotope-Labeled Compounds
Sodium Channel
Dopamine Receptor
SARS-CoV
|
Others
|
Fluphenazine-d8 is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 [2] .
|
-
- HY-N11902
-
|
SARS-CoV
|
Infection
|
1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one is a potent nucleocapsid (N) protein inhibitor can be isolated from Curcuma kwangsiensis. 1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one exhibits excellent antiviral activity against HCoV-OC43 and SARS-CoV-2,with EC50 values of 0.16 μM and 0.17 μM, respectively .
|
-
- HY-N1913
-
Dan shen suan A; Salvianic acid A
|
Keap1-Nrf2
NF-κB
Reactive Oxygen Species
SARS-CoV
Apoptosis
|
Infection
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Danshensu (Dan shen suan A), an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research [2] .
|
-
- HY-N1913A
-
Dan shen suan A sodium; Salvianic acid A sodium
|
Keap1-Nrf2
NF-κB
Reactive Oxygen Species
SARS-CoV
Apoptosis
|
Infection
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Danshensu (Dan shen suan A) sodium, an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu sodium reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu sodium displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu sodium has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research [2] .
|
-
- HY-A0081R
-
|
Dopamine Receptor
SARS-CoV
Sodium Channel
|
Neurological Disease
Cancer
|
Fluphenazine (dihydrochloride) (Standard) is the analytical standard of Fluphenazine (dihydrochloride). This product is intended for research and analytical applications. Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 [2] .
|
-
- HY-163783
-
|
Casein Kinase
|
Infection
|
CSNK2-IN-1 is a potent and selective CSNK2 inhibitor with IC50 of 1.7 nM and 0.66 nM for CSNK2A1 and CSNK2A2, respectively. CSNK2-IN-1 has antiviral activity against beta-coronaviruses such as SARS-CoV-2 and MHV. CSNK2-IN-1 has good solubility, metabolic stability, and low cytotoxicity, but its plasma concentration in vivo decreases rapidly and is insufficient to achieve pharmacological effects. CSNK2-IN-1 can be used in the research of antiviral drug development .
|
-
- HY-B1400R
-
|
Parasite
SARS-CoV
|
Infection
Inflammation/Immunology
|
Diiodohydroxyquinoline (Standard) is the analytical standard of Diiodohydroxyquinoline. This product is intended for research and analytical applications. Diiodohydroxyquinoline (Iodoquinol, 5,7-Diiodo-8-hydroxyquinoline, 5,7-Diiodo-8-quinolinol) has an orally active and satisfactory antiparasitic properties. Diiodohydroxyquinoline exhibits mutagenic potential in mice and potent anti-SARS-CoV-2 activity with an EC50 value of 1.38 μM in VeroE6 cells. Diiodohydroxyquinoline's antimutagen is ascorbic acid. Diiodohydroxyquinoline is promising for research in inflammationin, testinal amebiasis, amebic liver abscess and chronic nonspecific diarrheas [2] .
|
-
- HY-13771
-
Ursodeoxycholate; Ursodiol; UDCA
|
G protein-coupled Bile Acid Receptor 1
FXR
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Infection
Metabolic Disease
Cancer
|
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active [2] .
|
-
- HY-B0879
-
|
Phosphatase
Sirtuin
Reverse Transcriptase
Topoisomerase
SARS-CoV
Parasite
Apoptosis
|
Infection
Cardiovascular Disease
Cancer
|
Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM) [2]. Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM) . Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor .Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .
|
-
- HY-108511A
-
|
Sigma Receptor
Apoptosis
SARS-CoV
|
Infection
Cancer
|
PB28 is a cyclohexylpiperazine derivative and a high affinity and selective sigma 2 (σ2) receptor agonist with a Ki of 0.68 nM. PB28 is also a σ1 antagonist with a Ki of 0.38 nM. PB28 is less affinity for other receptors. PB28 inhibits electrically evoked twitch in guinea pig bladder and ileum with EC50 values of 2.62 μM and 3.96 μM, respectively. PB28 can modulate SARS-CoV-2-human protein-protein interaction. PB28 induces caspase-independent apoptosis and has antitumor activity [2] .
|
-
- HY-108511
-
|
Sigma Receptor
Apoptosis
SARS-CoV
|
Infection
Cancer
|
PB28 dihydrochloride, a cyclohexylpiperazine derivative, is a high affinity and selective sigma 2 (σ2) receptor agonist with a Ki of 0.68 nM. PB28 dihydrochloride is also a σ1 antagonist with a Ki of 0.38 nM. PB28 dihydrochloride is less affinity for other receptors. PB28 dihydrochloride inhibits electrically evoked twitch in guinea pig bladder and ileum with EC50 values of 2.62 μM and 3.96 μM, respectively. PB28 dihydrochloride can modulate SARS-CoV-2-human protein-protein interaction. PB28 dihydrochloride induces caspase-independent apoptosis and has antitumor activity [2] .
|
-
- HY-D0837
-
Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene
|
Ser/Thr Protease
Thrombopoietin Receptor
|
Neurological Disease
Inflammation/Immunology
|
Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease [2] .
|
-
- HY-B0879A
-
Suramin hexasodium salt
|
Phosphatase
Sirtuin
Reverse Transcriptase
Topoisomerase
SARS-CoV
Parasite
Apoptosis
|
Infection
Cardiovascular Disease
Cancer
|
Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM) [2]. Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM) . Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor . Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .
|
-
- HY-15310
-
MK-933; CD-5024; K-237
|
Flavivirus
Dengue virus
Parasite
HIV
Mitophagy
HSV
SARS-CoV
Antibiotic
Autophagy
Bacterial
|
Infection
Cancer
|
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X4 and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import [2] . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .
|
-
- HY-113478S
-
|
Isotope-Labeled Compounds
|
Infection
Metabolic Disease
|
Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].
|
-
- HY-B0879AR
-
|
Phosphatase
Sirtuin
Reverse Transcriptase
Topoisomerase
SARS-CoV
Parasite
Apoptosis
|
Infection
Cardiovascular Disease
Cancer
|
Suramin (sodium salt) (Standard) is the analytical standard of Suramin (sodium salt). This product is intended for research and analytical applications. Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM) [2]. Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM) . Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor . Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .
|
-
- HY-D0837R
-
|
Ser/Thr Protease
Thrombopoietin Receptor
|
Neurological Disease
Inflammation/Immunology
|
Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease [2] .
|
-
- HY-15310R
-
|
Dengue virus
Flavivirus
Parasite
HIV
Mitophagy
HSV
SARS-CoV
Antibiotic
Autophagy
Bacterial
|
Infection
Cancer
|
Ivermectin (Standard) is the analytical standard of Ivermectin. This product is intended for research and analytical applications. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X4 and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import [2] . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .
|
-
- HY-N6972
-
|
Autophagy
SARS-CoV
Cytochrome P450
Apoptosis
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
Cepharanthine is a natural product that can be isolated from the plant Stephania cephalantha Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC50) and 90% inhibitory concentration (IC90) values of 1.90 and 4.46 µM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model [2] . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .
|
-
- HY-N6972R
-
|
Autophagy
SARS-CoV
Cytochrome P450
Apoptosis
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
Cepharanthine (Standard) is the analytical standard of Cepharanthine. This product is intended for research and analytical applications. Cepharanthine is a natural product that can be isolated from the plant Stephania?cephalantha?Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC50) and 90% inhibitory concentration (IC90) values of 1.90 and 4.46?μM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model [2] . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-D1270
-
|
Dyes
|
Direct Violet 1, an azo dye, is a textile dye. Direct Violet 1 is also the protein-protein interaction (PPI) between the SARS-CoV-2 spike protein and ACE2 inhibitor with IC50s of 1.47-2.63 μM [2].
|
-
- HY-B0961
-
Mercury dibromofluorescein disodium salt; ZP1
|
Dyes
|
Merbromin is a mixed inhibitor of the 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2, with an IC50 of 2.7 μM. Merbromin effectively inhibits the replication of the Zika virus (ZIKV) and shows anti-ZIKV activity by inhibiting ZIKVpro. Merbromin can also be used as a topical disinfectant for cuts and scrapes, and it serves as a biological dye [2].
|
-
- HY-D2342
-
|
Fluorescent Dyes/Probes
|
SARS-CoV-2 3CLpro probe-1 (Compound probe 3) is a selective and activity-based probe for the SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro probe-1 can detect endogenously expressed 3CLpro in SARS-CoV-2-infected cells .
|
Cat. No. |
Product Name |
Type |
-
- HY-D0837
-
Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene
|
Cell Assay Reagents
|
Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease [2] .
|
-
- HY-D0837R
-
|
Cell Assay Reagents
|
Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease [2] .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0012A
-
Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
|
-
- HY-P0012
-
Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al [2] .
|
-
- HY-16050
-
Aplidine; PM90001
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
Cancer
|
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( KD=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research [2].
|
-
- HY-P3492
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .
|
-
- HY-P10688
-
-
- HY-P10344
-
|
Fluorescent Dye
|
Infection
|
MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 is a fluorescent substrate used for fluorescence resonance energy transfer (FRET) protease assays. This substrate is employed to measure the activity of SARS-CoV-2 3CLpro .
|
-
- HY-18234
-
-
- HY-P5827
-
-
- HY-P4307
-
|
SARS-CoV
|
Infection
|
Antioxidant agent-9 is a peptide with the sequence Asp-Trp. Antioxidant agent-9 shows antioxidant activity. Antioxidant agent-9 also is potential as SARS-CoV-2 antiviral, with an affinity strength equal to Chloroquine (HY-17589A) and Favipiravir (HY-14768) [2].
|
-
- HY-P3626
-
SPL7013 free base
|
Bacterial
HCV
SARS-CoV
|
Infection
|
Astodrimer (SPL7013 free base) is a large (3-4 nm, ~ 16.5 kDa), negatively charged, highly-branched dendrimer, is a potent virucidal agent. Astodrimer shows antiviral and virucidal activity against a broad spectrum of viruses, including SARS-CoV-2, HIV-1, HSV-1, HSV-2, HPV. Astodrimer also has antibacterial properties [2] .
|
-
- HY-16050R
-
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
Cancer
|
Plitidepsin (Standard) is the analytical standard of Plitidepsin. This product is intended for research and analytical applications. Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( KD=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research [2].
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9807
-
SARS-CR3022; SARS-COV-2 Antibody-CR3022
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein [2].
|
-
- HY-P99556
-
AZD8895
|
SARS-CoV
|
Infection
|
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
|
-
- HY-P99103
-
LY-3853113; LY-COV1404
|
SARS-CoV
|
Infection
|
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy [2].
|
-
- HY-P99604
-
AZD-1061; COV2-2130
|
SARS-CoV
|
Infection
|
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
|
-
- HY-P99344
-
Anti-Human SARS-COV-2
|
SARS-CoV
|
Infection
|
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
|
-
- HY-P99347
-
-
- HY-P990816
-
|
Inhibitory Antibodies
|
Others
|
Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to SARS-CoV-2 S protein. The recommend isotype control of Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990814
-
|
Inhibitory Antibodies
|
Others
|
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to SARS-CoV-2 S protein. The recommend isotype control of Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990815
-
|
Inhibitory Antibodies
|
Others
|
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to SARS-CoV-2 S protein. The recommend isotype control of Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P99710
-
BI 767551; DZIF-10c
|
SARS-CoV
|
Infection
|
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 [2].
|
-
- HY-145644
-
C-135-LS; BMS-986414
|
SARS-CoV
|
Infection
Cancer
|
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
|
-
- HY-P99929
-
HFB-30132A
|
SARS-CoV
|
Inflammation/Immunology
|
Enuzovimab (HFB-30132A) is a mAb against SARS-COV-2 Omicron. Enuzovimab binds to spike (S) protein with high affinity .
|
-
- HY-P99341
-
REGN10933
|
SARS-CoV
|
Infection
|
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms [2].
|
-
- HY-P99104
-
COVI-AMG; STI-2020
|
SARS-CoV
|
Infection
|
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) [2].
|
-
- HY-P9802
-
SARS-COV-2 (2019-nCOV) Single-Domain Antibodies; Humanized Single Domain Antibody
|
SARS-CoV
|
Infection
|
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .
|
-
- HY-P990052
-
MAD-0004J08
|
SARS-CoV
|
Infection
|
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .
|
-
- HY-145642
-
ZRC3308-A7
|
SARS-CoV
|
Infection
|
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
- HY-145643
-
ZRC3308-B10
|
SARS-CoV
|
Infection
|
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
- HY-P99423
-
ADG 20
|
SARS-CoV
|
Infection
|
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
|
-
- HY-P99947
-
XVR011
|
SARS-CoV
|
Infection
|
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .
|
-
- HY-P99889
-
BRII-198
|
SARS-CoV
|
Infection
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2].
|
-
- HY-145641
-
BMS-986413; C-144-LS
|
SARS-CoV
|
Infection
|
Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain .
|
-
- HY-P990705
-
REGN-15160
|
SARS-CoV
|
Inflammation/Immunology
|
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990725
-
|
SARS-CoV
|
Inflammation/Immunology
|
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990768
-
|
SARS-CoV
|
Inflammation/Immunology
|
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990711
-
|
SARS-CoV
|
Inflammation/Immunology
|
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P990756
-
|
SARS-CoV
|
Inflammation/Immunology
|
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P990766
-
AZD3152
|
SARS-CoV
|
Inflammation/Immunology
|
Sipavibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P9801
-
SARS-COV-2 (2019-nCOV) Spike RBD Antibody
|
SARS-CoV
|
Infection
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
-
- HY-P99435
-
BRII-196
|
SARS-CoV
|
Infection
|
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants [2].
|
-
- HY-P99346
-
CT-P59
|
SARS-CoV
Angiotensin-converting Enzyme (ACE)
|
Infection
|
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
|
-
- HY-P99467
-
BMS 4182137; VIR 7832
|
SARS-CoV
|
Infection
|
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .
|
-
- HY-P99376
-
OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)
|
SARS-CoV
|
Infection
|
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
|
-
- HY-P99012
-
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection [2].
|
-
- HY-P99342
-
REGN10987
|
SARS-CoV
|
Infection
|
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .
|
-
- HY-P99901
-
VIS649
|
SARS-CoV
|
Inflammation/Immunology
Cancer
|
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) [2] .
|
-
- HY-P99340
-
VIR 7831
|
SARS-CoV
|
Infection
Cancer
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease [2].
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-126085
-
-
-
- HY-137984
-
-
-
- HY-N8599
-
-
-
- HY-N2016
-
-
-
- HY-163742
-
-
-
- HY-N11896A
-
-
-
- HY-N10118
-
-
-
- HY-N10604
-
-
-
- HY-N12384
-
-
-
- HY-N144101
-
-
-
- HY-126085R
-
-
-
- HY-N10605
-
-
-
- HY-B1624A
-
-
-
- HY-N8306
-
-
-
- HY-13512
-
-
-
- HY-18234A
-
-
-
- HY-N10109A
-
-
-
- HY-13433
-
-
-
- HY-N3445
-
-
-
- HY-N1996
-
-
-
- HY-N9351
-
-
-
- HY-N12697A
-
-
-
- HY-A0097
-
-
-
- HY-A0097A
-
-
-
- HY-N2355
-
-
-
- HY-16050
-
-
-
- HY-13512R
-
|
Human Gut Microbiota Metabolites
Microorganisms
Source classification
Endogenous metabolite
|
Ser/Thr Protease
SARS-CoV
|
Camostat (mesylate) (Standard) is the analytical standard of Camostat (mesylate). This product is intended for research and analytical applications. Camostat mesylate (Camostat mesilate) is an orally active, synthetic serine protease inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of TMPRSS2, shows antiviral activity against SARS-CoV-2. Camostat mesylate also inhibits the activity of prostasin, trypsin, and matriptase [2] .
|
-
-
- HY-N7073
-
-
-
- HY-107577
-
-
-
- HY-126419
-
-
-
- HY-N0063
-
-
-
- HY-N1996R
-
-
-
- HY-110066
-
-
-
- HY-B0157A
-
-
-
- HY-B0157
-
-
-
- HY-N10661
-
Ipom-F
|
Structural Classification
Natural Products
Ipomoea squamosa Choisy
Plants
Convolvulaceae
|
SARS-CoV
|
Ipomoeassin F is a potent and selective endoplasmic reticulum (ER) protein-translocation inhibitor by targeting the pore-forming subunit of the Sec61 complex (Sec61α) at the ER membrane. Ipomoeassin F selectively inhibits the ER membrane translocation of SARS-CoV-2 proteins. Ipomoeassin F block the ER translocation of secretory proteins and type I transmembrane proteins (TMPs), but not type III TMPs [2] .
|
-
-
- HY-16050R
-
-
-
- HY-N0063R
-
|
Structural Classification
Punica granatum L.
Source classification
Phenols
Polyphenols
Punicaceae
Plants
|
SARS-CoV
HBV
|
Punicalagin (Standard) is the analytical standard of Punicalagin. This product is intended for research and analytical applications. Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CLpro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19 [2] .
|
-
-
- HY-B0157AR
-
|
Structural Classification
Natural Products
Source classification
Endogenous metabolite
|
Histamine Receptor
Endogenous Metabolite
SARS-CoV
Influenza Virus
|
Ketotifen (fumarate) (Standard) is the analytical standard of Ketotifen (fumarate). This product is intended for research and analytical applications. Ketotifen (HC 20-511) fumarate is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen fumarate can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen fumarate also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen fumarate can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention [2] .
|
-
-
- HY-110066R
-
-
-
- HY-N12110
-
-
-
- HY-N11902
-
-
-
- HY-N1913
-
-
-
- HY-N1913A
-
-
-
- HY-13771
-
-
-
- HY-15310
-
-
-
- HY-15310R
-
-
-
- HY-N6972
-
-
-
- HY-N6972R
-
|
Structural Classification
Alkaloids
Stephania cepharantha Hayata
Plants
Isoquinoline Alkaloids
Menispermaceae
Stephania japonica (Thunb.) Miers
|
Autophagy
SARS-CoV
Cytochrome P450
Apoptosis
Parasite
|
Cepharanthine (Standard) is the analytical standard of Cepharanthine. This product is intended for research and analytical applications. Cepharanthine is a natural product that can be isolated from the plant Stephania?cephalantha?Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC50) and 90% inhibitory concentration (IC90) values of 1.90 and 4.46?μM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model [2] . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .
|
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-145119S
-
|
GS-621763-d1 is the deuterium labeled GS-621763 (HY-145119) . GS-621763, an orally bioavailable proagent of GS-441524, shows antiviral activity against SARS-CoV-2 pathogenesis in mice [2].
|
-
-
- HY-B0190S1
-
|
Nafamostat formate salt- 13C6 is the 13C labeled Nafamostat. Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat blocks activation of SARS-CoV-2 [2] .
|
-
-
- HY-B0372AS
-
|
Bromhexine-d3 (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions[1][2][3][4].
|
-
-
- HY-P5168S
-
|
GPSVFPLAPSSK- 13C6 is the 13C labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies [2].
|
-
-
- HY-10241S
-
|
Simeprevir- 13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].
|
-
-
- HY-B0462AS
-
|
Azelastine- 13C,d3 is deuterium labeled Azelastine. Azelastine, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2[1][2][3][4].
|
-
-
- HY-W031727S
-
|
Hydroxychloroquine-d4-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].
|
-
-
- HY-W031727S1
-
|
Hydroxychloroquine-d5 is the deuterium labeled Hydroxychloroquine[1]. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].
|
-
-
- HY-169220S
-
|
RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and DHODH inhibitor with IC50 values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5) .
|
-
-
- HY-B1370S
-
|
Hydroxychloroquine-d4 (sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].
|
-
-
- HY-100442S
-
|
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice [2] .
|
-
-
- HY-100442S1
-
|
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice [2] .
|
-
-
- HY-10237S
-
|
Boceprevir-d9 is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].
|
-
-
- HY-17589AS
-
1 Publications Verification
|
Chloroquine-d5 is deuterium labeled Chloroquine. Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].
|
-
-
- HY-17589S1
-
|
Chloroquine-d4 (phosphate) is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].
|
-
-
- HY-17589S
-
|
Chloroquine-d5 (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].
|
-
-
- HY-14904AS
-
|
Umifenovir-d6 (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells[1][2]. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity[3].
|
-
-
- HY-B0462S
-
|
Azelastine- 13C,d3 (hydrochloride) is the 13C- and deuterium labeled Azelastine hydrochloride. Azelastine- 13C,d3 (hydrochloride), an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine- 13C,d3 (hydrochloride) can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2[1][2][3][4].
|
-
-
- HY-104077S1
-
|
Remdesivir-d4 is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].
|
-
-
- HY-135853S
-
|
Molnupiravir-d7 is the deuterium labeled Molnupiravir. Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].
|
-
-
- HY-169222S
-
|
RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC50 values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively .
|
-
-
- HY-145119AS
-
|
Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 [2].
|
-
-
- HY-104077S2
-
|
Remdesivir impurity 9-d4 is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].
|
-
-
- HY-15148S1
-
|
Tipranavir-d7 is deuterated labeled Tipranavir (HY-15148). Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM [2]. Tipranavir inhibits SARS-CoV-2 3CL pro activity .
|
-
-
- HY-10235S
-
|
Telaprevir-d4 is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].
|
-
-
- HY-119980S
-
|
Fluphenazine-d8 is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 [2] .
|
-
-
- HY-113478S
-
|
Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-D2342
-
|
|
Alkynes
|
SARS-CoV-2 3CLpro probe-1 (Compound probe 3) is a selective and activity-based probe for the SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro probe-1 can detect endogenously expressed 3CLpro in SARS-CoV-2-infected cells .
|
-
- HY-168152
-
|
|
Alkynes
|
SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) is an allosteric inhibitor for SARS-CoV-2 3CLpro with an IC50 of 0.43 μM. SARS-CoV-2 3CLpro-IN-26 exhibits good cell permeability and is able to effectively cross the cell membrane, after co-incubation with Vero-E6 cells .
|
-
- HY-163785
-
|
|
Azide
|
1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructural protein macodomain SARS-CoV-2 NSP3 Mac1 with an IC50 of 30 nM .
|
-
- HY-161792
-
|
|
Azide
|
N3-C5-O-C-Boc is a linker, which can be utilized for the synthesis of PROTAC SARS-CoV-2 Mpro degrader-3 (HY-161789) .
|
-
- HY-162507
-
|
|
Alkynes
|
2'-RIBOTAC-U recruiter-linker (Compound 9) consists of RNase L recruiter and linker. 2'-RIBOTAC-U recruiter-linker is reacted separately with 2’-azido-uridine or 5’-azidomethyl-uridine via copper-catalyzed click chemistry, resulting in the formation of 2’-RIBOTAC-U and 5’-RIBOTAC-U, respectively. 2’-RIBOTAC-U has anti-SARS-CoV-2 activity .
|
-
- HY-161793
-
|
|
Azide
|
(S,R,S)-AHPC-NHCO-C-O-C5-N3 is a conjugate of ligand for E3 ligase (HY-125845) and linker (HY-161792). (S,R,S)-AHPC-NHCO-C-O-C5-N3 can be utilized for synthesis of PROTAC SARS-CoV-2 Mpro degrader-3 (HY-161789) .
|
Cat. No. |
Product Name |
|
Classification |
-
- HY-160554
-
|
|
Cationic Lipids
|
C12-113 is a lipidoid delivery agent that can be used to transfect siRNA into cells. C12-113 can also be combined with other lipids to form lipid nanoparticles (LNPs) for the delivery of mRNA encoding the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice [2].
|
-
- HY-159700
-
|
|
Cationic Lipids
|
AA3-DLin is an ionizable cationic lipid with a pKa value of 5.8. AA3-DLin is used to delivery mRNA combined with lipid nanoparticles (LNPs). AA3-DLin LNP COVID-19 vaccines encapsulating SARS CoV-2 spike mRNAs successfully induces strong immunogenicity in a BALB/c mouse model .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: